

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number  
**WO 2005/003096 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 223/16**,  
A61K 31/55, A61P 25/00

(21) International Application Number:  
PCT/US2004/019670

(22) International Filing Date: 16 June 2004 (16.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/479,280 17 June 2003 (17.06.2003) US

(71) Applicant (for all designated States except US): **ARENA  
PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy  
Ridge Drive, San Diego, CA 92121-3223 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMITH, Brian**  
[US/US]; 13182 Mesa Crest Place, San Diego, California  
92129 (US). **GILSON, Charles, III** [US/US]; 7176 Salizar  
Street, San Diego, California 92111 (US). **SCHULTZ,  
Jeffrey** [US/US]; 10156 Prairie Fawn Drive, San Diego,  
California 92127 (US). **SMITH, Jeffrey** [US/US]; 10547  
Caminito Basswood, San Diego, California 92131 (US).

(74) Agents: **SPRUCE, Lyle** et al.; Arena Pharmaceuticals,  
Inc., 6166 Nancy Ricge Drive, San Diego, California  
92121-3223 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT<sub>2C</sub> RECEPTOR ASSOCIATED DIS-  
EASES

(57) Abstract: The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I),  
that are modulators of the 5HT<sub>2C</sub> receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or  
treatment of 5HT<sub>2C</sub> receptor associated diseases, conditions or disorders, such as, obesity and related disorders.

WO 2005/003096 A1

BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT<sub>2C</sub> RECEPTOR ASSOCIATED DISEASES**FIELD OF THE INVENTION**

5           The present invention relates to certain substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT<sub>2C</sub> receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT<sub>2C</sub> receptor associated diseases, conditions or disorders, such as, obesity and related disorders.

**BACKGROUND OF THE INVENTION**

10           Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as, but not limited to, type II diabetes, hypertension, stroke, certain forms of cancers and gallbladder disease.

          Obesity has become a major healthcare issue in the Western World and increasingly in  
15   some third world countries. The increase in the number of obese people is due largely to the increasing preference for high fat content foods but also, and this can be a more important factor, the decrease in activity in most people's lives. In the last 10 years there has been a 30% increase in the incidence of obesity in the USA and that about 30% of the population of the USA is now considered obese. In spite of the growing awareness of the health concerns linked to obesity the  
20   percentage of individuals that are overweight or obese continue to increase. In fact, the percentage of children and adolescents who are defined as overweight has more than doubled since the early 1970s and about 13 percent of children and adolescents are now seriously overweight. The most significant concern, from a public health perspective, is that children who are overweight grow up to be overweight or obese adults, and accordingly are at greater risk for major health problems.  
25   Therefore, it appears that the number of individuals that are overweight or obese will continue to increase.

          Whether someone is classified as overweight or obese is generally determined on the basis of his or her body mass index (BMI) which is calculated by dividing their body weight (kilograms - Kg) by their height squared (meters squared - m<sup>2</sup>). Thus, the units for BMI are Kg/m<sup>2</sup>. The BMI is  
30   more highly correlated with body fat than any other indicator of height and weight. A person is considered overweight when they have a BMI in the range of 25-30 kg/m<sup>2</sup>. Whereas a person with a BMI over 30 kg/m<sup>2</sup> is classified as obese and obesity is further divided into three classes, Class I (BMI of about 30 to about 34.9 kg/m<sup>2</sup>), Class II (BMI of about 35 to 39.9 kg/m<sup>2</sup>) and Class III (about 40 kg/m<sup>2</sup> or greater); see TABLE 1 below for complete classifications.

**TABLE 1**  
**CLASSIFICATION OF WEIGHT BY BODY MASS INDEX (BMI)**

| BMI       | CLASSIFICATION              |
|-----------|-----------------------------|
| < 18.5    | Underweight                 |
| 18.5-24.9 | Normal                      |
| 25.0-29.9 | Overweight                  |
| 30.0-34.9 | Obesity (Class I)           |
| 35.0-39.9 | Obesity (Class II)          |
| > 40      | Extreme Obesity (Class III) |

As the BMI increases for an individual there is an increased risk of morbidity and mortality relative to an individual with normal BMI. Accordingly, overweight and obese individuals (BMI of about 25 kg/m<sup>2</sup> and above) are at increased risk for physical ailments such as, but not limited to, high blood pressure, cardiovascular disease (particularly hypertension), high blood cholesterol, dyslipidemia, type II (non-insulin dependent) diabetes, insulin resistance, glucose intolerance, hyperinsulinemia, coronary heart disease, angina pectoris, congestive heart failure, stroke, gallstones, cholecystitis and cholelithiasis, gout, osteoarthritis, obstructive sleep apnea and respiratory problems, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation), diseases of reproduction (such as sexual dysfunction, both male and female, including male erectile dysfunction), bladder control problems (such as stress incontinence), uric acid nephrolithiasis, psychological disorders (such as depression, eating disorders, distorted body image, and low self esteem). Research has shown that even a modest reduction in body weight can correspond to a significant reduction in the risk of developing other ailments, such as, but not limited to, coronary heart disease.

As mentioned above, obesity increases the risk of developing cardiovascular diseases. Coronary insufficiency, atheromatous disease, and cardiac insufficiency are at the forefront of the cardiovascular complications induced by obesity. The incidence of coronary diseases is doubled in subjects less than 50 years of age who are 30% overweight. The diabetes patient faces a 30% reduced lifespan. After age 45, people with diabetes are about three times more likely than people without diabetes to have significant heart disease and up to five times more likely to have a stroke. These findings emphasize the inter-relations between risks factors for NIDDM and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of obesity [Perry, I. J., et al. *BMJ* 310, 560-564 (1995)]. It is estimated that if the entire

population had an ideal weight, the risk of coronary insufficiency would decrease by 25% and the risk of cardiac insufficiency and of cerebral vascular accidents by 35%.

Diabetes has also been implicated in the development of kidney disease, eye diseases and nervous-system problems. Kidney disease, also called nephropathy, occurs when the kidney's "filter mechanism" is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails. Diabetes is also a leading cause of damage to the retina and increases the risk of cataracts and glaucoma. Finally, diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together, diabetes complications are one of the nation's leading causes of death.

The first line of treatment for individuals that are overweight or obese is to offer diet and life style advice, such as, reducing the fat content of their diet and increasing their physical activity. However many patients find these difficult to maintain and need additional help from drug therapy to sustain results from these efforts.

Most currently marketed products have been unsuccessful as treatments for obesity owing to a lack of efficacy or unacceptable side-effect profiles. The most successful drug so far was the indirectly acting 5-hydroxytryptamine (5-HT) agonist d-fenfluramine (Redux<sup>TM</sup>) but reports of cardiac valve defects in up to one third of the patient population led to its withdrawal by the FDA in 1998.

In addition, two drugs have recently been launched in the USA and Europe: Orlistat (Xenical<sup>TM</sup>), a drug that prevents absorption of fat by the inhibition of pancreatic lipase, and Sibutramine (Reductil<sup>TM</sup>), a 5-HT/noradrenaline re-uptake inhibitor. However, side effects associated with these products may limit their long-term utility. Treatment with Xenical<sup>TM</sup> is reported to induce gastrointestinal distress in some patients, while Sibutramine has been associated with raised blood pressure in some patients.

Serotonin (5-HT) neurotransmission plays an important role in numerous physiological processes both in health and in psychiatric disorders. 5-HT has been implicated in the regulation of feeding behavior for some time. 5-HT works by inducing a feeling of fullness or satiety so eating stops earlier and fewer calories are consumed. It has been shown that a stimulatory action of 5-HT on the 5HT<sub>2C</sub> receptor plays an important role in the control of eating and in the anti-obesity effect of d-fenfluramine. As the 5HT<sub>2C</sub> receptor is expressed in high density in the brain (notably in the limbic structures, extrapyramidal pathways, thalamus and hypothalamus i.e. PVN and DMH, and predominantly in the choroid plexus) and is expressed in low density or is absent in peripheral tissues, a selective 5HT<sub>2C</sub> receptor agonist can be an effective and safe anti-obesity agent. Also, 5HT<sub>2C</sub> knockout mice are overweight with cognitive impairment and susceptibility to seizure thus

establishing the clear use for a 5HT<sub>2C</sub> receptor agonist in 5HT<sub>2C</sub> receptor associated diseases or disorders.

The 5HT<sub>2C</sub> receptor plays a role in obsessive compulsive disorder, some forms of depression, and epilepsy. Accordingly, 5HT<sub>2C</sub> receptor agonists can have anti-panic properties, and properties useful for the treatment of sexual dysfunction. In addition, 5HT<sub>2C</sub> receptor agonists are useful for the treatment of psychiatric symptoms and behaviors in individuals with eating disorders such as, but not limited to, anorexia nervosa and bulimia nervosa. Individuals with anorexia nervosa often demonstrate social isolation. Anorexic individuals often present symptoms of being depressed, anxious, obsession, perfectionistic traits, and rigid cognitive styles as well as sexual disinterest. Other eating disorders include, anorexia nervosa, bulimia nervosa, binge eating disorder (compulsive eating) and ED-NOS (i.e., eating disorders not otherwise specified - an official diagnosis). An individual diagnosed with ED-NOS possess atypical eating disorders including situations in which the individual meets all but a few of the criteria for a particular diagnosis. What the individual is doing with regard to food and weight is neither normal nor healthy.

In addition, the 5HT<sub>2C</sub> receptor is also involved in other diseases, conditions and disorders; such as Alzheimer Disease (AD). Therapeutic agents currently prescribed for Alzheimer's disease (AD) are cholinomimetic agents that act by inhibiting the enzyme acetylcholinesterase. The resulting effect is increased levels of acetylcholine, which modestly improves neuronal function and cognition in patients with AD. Although, dysfunction of cholinergic brain neurons is an early manifestation of AD, attempts to slow the progression of the disease with these agents have had only modest success, perhaps because the doses that can be administered are limited by peripheral cholinergic side effects, such as tremors, nausea, vomiting, and dry mouth. In addition, as AD progresses, these agents tend to lose their effectiveness due to continued cholinergic neuronal loss.

Therefore, there is a need for agents that have beneficial effects in AD, particularly in alleviating symptoms by improving cognition and slowing or inhibiting disease progression, without the side effects observed with current therapies. Therefore, serotonin 5HT<sub>2C</sub> receptors, which are exclusively expressed in brain, are attractive targets.

A major feature of AD is the formation of senile plaques made of amyloid deposits in a selected area of the brain. New therapies should focus on prevention of the production of these senile plaques. An amyloid deposit composed mainly of beta-amyloid peptide (A $\beta$ ) occupies the plaque center. A $\beta$  is a peptide of 40 to 43 residues derived from a larger amyloid precursor protein, APP [Selkoe DJ, et al. *Ann Rev Neurosci*, 1994, 17:489-517]. APP is a ubiquitous transmembrane glycoprotein that is present at high levels in brain cells. APP also exists as secreted forms. By cleavage in the A $\beta$  region of APP, the long N-terminal fragment (secreted APP, APPs) is secreted

into the extracellular space. The rate of A $\beta$  production appears to be inversely coupled to rate APPs secretion. In several cell cultures, APPs secretion was accompanied by reductions in secreted A $\beta$  [Buxbaum JD, et al. *Proc Nat Acad Sci*, 1993, 90:9195-9198; Gabuzda D, et al. *J Neurochem*, 1993, 61:2326-2329; Hung AY, et al. *J Biol Chem*, 1993, 268:22959-22962; and Wolf BA, et al. *J Biol Chem*, 1995, 270:4916-4922], suggesting that stimulated secretory processing of APP into secreted APPs is associated with reduced formation of potentially amyloidogenic derivatives, or plaques.

APPs is found in plasma and cerebrospinal fluid [Ghisso J, et al. *Biochem Biophys Res Commun*, 1989, 163:430-437; and Podlisny MB, et al. *Biochem Biophys Res Commun*, 1990, 167:1094-1101]. Considering the abundance of both membrane-bound APP and APPs, they are likely to have significant biological functions. Current knowledge about APP functions indicates APP is critically required for the maintenance of neuronal and synaptic structure and function. Membrane-bound APP has been suggested to have a receptor-like structure [Kang J, et al. *Nature*, 1987, 325:733-736], with the cytoplasmic domain capable of complexing with a GTP-binding protein [Nishimoto I, et al. *Nature*, 1993, 362:75-79]. Membrane-embedded full-length APP might also have a cell adhesion function [Qiu W., et al. *J Neurosci*, 1995, 15:2157-2167].

APPs has been shown to be neurotrophic and neuroprotective in vitro [Mattson MP, et al. *Neuron*, 1993, 10:243-254; and Qiu W., et al. *J Neurosci*, 1995, 15:2157-2167]. Other proposed functions for APPs include the regulation of blood coagulation [Cole GM, et al. *Biochem Biophys Res Commun*, 1990, 170:288-295; Smith RP, et al. *Science*, 1990, 248:1126-1128; and Van Nostrand et al. *Science*, 1990, 248:745-748], wound-healing [Cunningham JM, et al. *Histochemistry*, 1991, 95:513-517], extracellular protease activity [Oltersdorf T, et al. *Nature (London)*, 1989, 341:144-147; and Van Nostrand WE, et al. *Nature*, 1989, 341:546-548], neurite extension [Jin L., et al. *J Neurosci*, 1994, 14:5461-5470; and Robakis NK, et al. in *Molecular Biology of Alzheimer's Disease*. (T. Miyatake, D.J. Selkoe and Y. Ihara, ed.), 1990, pp. 179-188, Elsevier Science Publishers B.V., Amsterdam], cell adhesiveness [Schubert D, et al. *Neuron*, 1989, 3:689-694], cell growth, [Bhasin R., et al. *Proc Natl Acad Sci USA*, 1991, 88:10307-10311; and Saitoh T., *Cell*, 1989, 58:615-622], and differentiation [Araki W., et al. *Biochem Biophys Res Commun*, 1991, 181:265-271; Milward EA, et al. *Neuron*, 1991, 9:129-137; and Yamamoto K, et al. *J Neurobiol*, 1994, 25:585-594].

The non-selective serotonin 5HT<sub>2C</sub> agonist dexnorfenfluramine (DEXNOR) stimulated amyloid precursor protein (APPs) secretion in guinea pigs while reducing levels of A $\beta$  production in vivo following repeat administration [Arjona A, et al. "Effect of a 5HT<sub>2C</sub> serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs," *Brain Res*, 2002,

951:135-140]. Guinea pigs were chosen because guinea pig and human APP exhibit 98% sequence homology [Beck M, et al. *Biochem Biophys Acta*, 1997, 1351:17-21], the proteins are processed similarly [Beck M., et al. *Neuroscience*, 1999, 95:243-254], and the A $\beta$  peptide sequences are identical [Johnstone EM, et al. *Brain Res Mol Brain Res*, 1991, 10:299-305]. Although DEXNOR is non-selective, the observed effects were attenuated by a selective serotonin 5HT<sub>2C</sub> antagonist, while a selective serotonin HT<sub>2A</sub> antagonist did not reverse the DEXNOR effects, indicating the serotonin 5HT<sub>2C</sub> receptors are the most relevant target for this effect.

In addition, 5-HT stimulates APPs ectodomain secretion via the serotonin 5HT<sub>2A</sub> and 5HT<sub>2C</sub> receptors [Nitsch RM, et al. *J Biol Chem*, 1996, 271(8):4188-4194]. In this study, researchers stimulated 3T3 fibroblasts with serotonin (5-HT), which were stably expressing serotonin 5HT<sub>2A</sub> or 5HT<sub>2C</sub> receptors. 5-HT increased APPs secretion in a dose-dependent manner in both cell lines. Maximal stimulation of APPs secretion peaked at about 4-fold. Selective serotonin 5HT<sub>2A</sub> and 5HT<sub>2C</sub> antagonists blocked the effects in each cell line.

A serotonin 5HT<sub>2C</sub> receptor agonist can be effective for treating AD and preventing senile plaques. Support for this claim comes from the fact that A $\beta$  is known to be neurotoxic and a key component in senile plaques involved in AD, APPs secretion and A $\beta$  levels seem to be inversely related, and serotonin 5HT<sub>2C</sub> agonists increase levels of APPs *in vitro* in cell lines stably expressing serotonin 5HT<sub>2C</sub> receptors while *in vivo* serotonin 5HT<sub>2C</sub> agonists increase levels of APPs and decrease levels of A $\beta$  as measured in cerebral spinal fluid of guinea pigs.

Evidence exists supporting the use of a compound of the present invention with agonist activity at the serotonin 5HT<sub>2C</sub> receptor for the treatment of AD. The compound of the invention can be used alone or in combination with another agent or agents (such as but not limited to AChE inhibitors) that are typically prescribed for AD.

Another disease, disorder or condition that can be associated with the function of the 5HT<sub>2C</sub> receptor is erectile dysfunction (ED). Erectile dysfunction is the inability to achieve or maintain an erection sufficiently rigid for intercourse, ejaculation, or both. An estimated 20-30 million men in the United States have this condition at some time in their lives. The prevalence of the condition increases with age. Five percent of men 40 years of age report ED. This rate increases to between 15% and 25% by the age of 65, and to 55% in men over the age of 75 years.

Erectile dysfunction can result from a number of distinct problems. These include loss of desire or libido, the inability to maintain an erection, premature ejaculation, lack of emission, and inability to achieve an orgasm. Frequently, more than one of these problems presents themselves simultaneously. The conditions may be secondary to other disease states (typically chronic conditions), the result of specific disorders of the urogenital system or endocrine system, secondary

to treatment with pharmacological agents (e.g. antihypertensive drugs, antidepressant drugs, antipsychotic drugs, etc.) or the result of psychiatric problems. Erectile dysfunction, when organic, is primarily due to vascular irregularities associated with atherosclerosis, diabetes, and hypertension.

There is evidence for use of a serotonin 5HT<sub>2C</sub> agonist for the treatment of sexual dysfunction in males and females. The serotonin 5HT<sub>2C</sub> receptor is involved with the processing and integration of sensory information, regulation of central monoaminergic systems, and modulation of neuroendocrine responses, anxiety, feeding behavior, and cerebrospinal fluid production [Tecott, L.H., et al. *Nature* 374: 542-546 (1995)]. In addition, the serotonin 5HT<sub>2C</sub> receptor has been implicated in the mediation of penile erections in rats, monkeys, and humans.

The exact mechanism by which 5HT<sub>2C</sub> receptors mediate penile erections remains unknown. However, there is good evidence, indirect and direct, supporting the role of serotonin 5HT<sub>2C</sub> receptors in the mediation of penile erections. Anatomical studies have shown that the penis receives autonomic innervation from sympathetic and parasympathetic nuclei located in the spinal cord [Pescatori ES, et al. *J Urol* 1993; 149: 627-32]. In agreement, experimental and clinical data support that penile erections are controlled by a spinal reflex. A closer analysis showed that activation of 5HT<sub>2</sub> spinal receptors facilitated pudendal reflex in anesthetized cats [Danuser H and Thor KB, *Br J Pharmacol* 1996; 118: 150-4]. Accordingly, stimulation of 5HT<sub>2C</sub> receptors has been shown to be proerectile [Millan MJ, et al. *European Journal of Pharmacology* 1997; 325], and 5HT<sub>2C</sub> receptors have been described on proerectile spinal parasympathetic neurons [Bancila M et al. *Neuroscience* 1999; 92: 1523-37].

Indirect evidence comes from the research and reports of the side effects induced by the use of selective serotonin reuptake inhibitors (SSRIs). SSRIs have demonstrated antagonist action at the serotonin 5HT<sub>2C</sub> receptors [Jenck et al. *European Journal of Pharmacology* 231: 223-229 (1993); Lightowler et al. *European Journal of Pharmacology* 296: 137-43 (1996); and Palvimaki, E., et al. *Psychopharmacology* 126: 234-240 (1996)]. Among the most derogatory side effects of SSRIs noted in humans is increased difficulty in attaining penile erection. Although SSRIs have a rich pharmacological profile, it is believed that the antagonist effects of SSRIs at the 5HT<sub>2C</sub> receptors could be implicated in the inhibition of penile erections [Palvimaki, E., et al. *Psychopharmacology* 126: 234-240 (1996)].

Further evidence comes from studies with a variety of compounds with known agonist activity for the serotonin 5HT<sub>2C</sub> receptor. Pharmacologic studies with rats and rhesus monkeys provide direct evidence of the proerectile properties of agonist of the serotonin 5-HT<sub>2C</sub> receptor [Millan MJ, et al. *European Journal of Pharmacology* 1997; 325; and Pomerantz, et al. *European Journal of Pharmacology* 243:227-34 (1993)]. These pro-erectile effects were unaffected by antagonists for




the serotonin 5HT<sub>2A</sub> and 5HT<sub>2B</sub> receptors, respectively. Antagonists of the serotonin 5HT<sub>2C</sub> receptors attenuated the proerectile effects of the 5-HT<sub>2C</sub> agonists. The inhibition action corresponded to each antagonist's affinity for the 5-HT<sub>2C</sub> receptors. In addition, agonists of the serotonin 5HT<sub>2A</sub> and 5HT<sub>2B</sub> receptors did not elicit penile erections.

In summary, the 5HT<sub>2C</sub> receptor is a validated and well-accepted receptor target for the prophylaxis and/or treatment of 5HT<sub>2C</sub> mediated receptor diseases and disorders, such as, obesity, eating disorders, psychiatric disorders, Alzheimer Disease, sexual dysfunction and disorders related thereto. It can be seen that there exists a need for selective 5HT<sub>2C</sub> receptor agonists that can safely address these needs. The present invention is directed to these, as well as other, important ends.

### SUMMARY OF THE INVENTION

The present invention is drawn to compounds which bind to and modulate the activity of the 5HT<sub>2C</sub> receptor, and uses thereof. The term 5HT<sub>2C</sub> receptor as used herein includes the human sequences found in GeneBank accession number AF498983, naturally-occurring allelic variants, mammalian orthologs, and recombinant mutants thereof.

One aspect of the present invention pertains to certain substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives as represented by Formula (I):



wherein:

R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>2</sub> is C<sub>1-4</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or CH<sub>2</sub>OH; and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are each independently H, C<sub>1-4</sub> alkyl, amino, cyano, halogen, C<sub>1-4</sub> haloalkyl, nitro or OH; or

a pharmaceutically acceptable salt, hydrate and solvate thereof;

provided that when R<sub>2</sub> is C<sub>1-4</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-4</sub> alkyl, and CH<sub>2</sub>OH then R<sub>3</sub> and R<sub>6</sub> are not both hydrogen.

Some embodiments of the present invention are compounds of Formula (I) wherein the compounds are the *R* enantiomers.

Some embodiments of the present invention are compounds of Formula (I) wherein the compounds are the *S* enantiomers.

Another aspect of the present invention also pertains to pharmaceutical compositions comprising one or more compounds of the invention, and one or more pharmaceutically acceptable carriers.

Another aspect of the present invention pertains to methods of modulating a 5HT<sub>2C</sub> receptor  
5 comprising contacting said receptor with a therapeutically effective amount or dose of a compound as described herein. Preferably, compounds of the present invention are agonists of the 5HT<sub>2C</sub> receptor.

Another aspect of the present invention pertains to methods of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular  
10 disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof.

Another aspect of the present invention pertains to methods of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount or dose of  
15 a compound of the present invention or a pharmaceutical composition thereof.

Another aspect of the present invention pertains to methods of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof.

Another aspect of the present invention pertains to methods of controlling weight gain of an  
20 individual comprising administering to said individual suffering from weight control a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof.

Another aspect of the present invention pertains to methods of producing a pharmaceutical composition comprising admixing at least one compound of the present invention and at least one  
25 pharmaceutically acceptable carrier.

Another aspect of the present invention pertains to compounds, as described herein, for use in a method of treatment of the human or animal body by therapy.

Another aspect of the present invention pertains to compounds, as described herein, for use in a method of prophylaxis or treatment of disorders of the central nervous system; damage to the  
30 central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea of the human or animal body by therapy.

Another aspect of the present invention pertains to use of compounds, as described herein, for the manufacture of a medicament for use in the treatment or prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders;

gastrointestinal disorders; diabetes insipidus or sleep apnea.

In some embodiments, the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension. In further  
5       embodiments, the disorder of the central nervous system is obesity. In further embodiments, the disorder of the central nervous system is Alzheimer disease. In further embodiments, the sexual dysfunction is Male erectile dysfunction.

In some embodiments, the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases, toxic CNS diseases or infective CNS diseases. In further embodiments,  
15       the damage to the central nervous system is by encephalitis or meningitis.

In some embodiments, the cardiovascular disorder is thrombosis.

In some embodiments, the gastrointestinal disorder is dysfunction of gastrointestinal motility.

In some embodiments, the invention pertains to methods for alleviation of a symptom of  
20       any of the diseases, conditions or disorders mentioned herein.

In some embodiments, the individual is a mammal.

In some embodiments, the individual is a mammal and preferably, the mammal is a human.

In further embodiments, the human has a body mass index of about 18.5 to about 45.

In further embodiments, the human has a body mass index of about 25 to about 45.

25       In further embodiments, the human has a body mass index of about 30 to about 45.

In further embodiments, the human has a body mass index of about 35 to about 45.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

30       For clarity and consistency, the following definitions will be used throughout this patent document.

**AGONISTS** shall mean moieties that interact and activate the receptor, such as the 5HT<sub>2c</sub> receptor and initiates a physiological or pharmacological response characteristic of that receptor. For example, when moieties activate the intracellular response upon binding to the receptor, or enhance GTP

binding to membranes.

The term **ANTAGONISTS** is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.

#### **CHEMICAL GROUP, MOIETY OR RADICAL:**

As used herein, the term “**alkyl**” is intended to denote hydrocarbon compounds including straight chain, branched and cyclic hydrocarbons, including for example but not limited to methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, tert-butyl, cyclobutyl, cyclopropylmethyl, n-pentyl, isopentyl, tert-pentyl, cyclopentyl, cyclopentylmethyl, n-hexyl, cyclohexyl, and the like. The term “**C<sub>1-8</sub> alkyl**” refers to an alkyl group containing 1 to 8 carbon atoms. Likewise, the term “**C<sub>1-4</sub> alkyl**” refers to an alkyl group containing 1 to 4 carbon atoms. Throughout this specification, it should be understood that the term alkyl is intended to encompass both non-cyclic hydrocarbon compounds and cyclic hydrocarbon compounds. In some embodiments of the compounds of the invention, alkyl groups are non-cyclic. In further embodiments, alkyl groups are cyclic, and in further embodiments, alkyl groups are both cyclic and noncyclic. Where no preference is specified, the term “alkyl” is intended to denote groups are both cyclic and non-cyclic.

The term “**amino**” denotes the group  $\text{-NH}_2$ .

The term “**cyano**” denotes the group  $\text{-CN}$ .

The term “**C<sub>1-4</sub> haloalkyl**” denotes an alkyl group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted and a fully substituted C<sub>1-4</sub> haloalkyl can therefore be represented by the formula  $\text{C}_n\text{L}_{2n+1}$  wherein L is a halogen; when more than one halogen is present then they may be the same or different and selected from the group consisting of F, Cl, Br or I. Examples of C<sub>1-4</sub> haloalkyl groups include: fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl and the like.

The term “**halogen**” or “**halo**” denotes to a fluoro, chloro, bromo or iodo group.

The term “**nitro**” refers to the group  $\text{-NO}_2$ .

**COMPOSITION** shall mean a material comprising at least two compounds or two components; for example, and not limitation, a Pharmaceutical Composition is a Composition.

**CONTACT** or **CONTACTING** shall mean bringing the indicated moieties together,

whether in an in vitro system or an in vivo system. Thus, "contacting" a 5HT<sub>2C</sub> receptor with a compound of the invention includes the administration of a compound of the present invention to an individual, preferably a human, having a 5HT<sub>2C</sub> receptor, as well as, for example, introducing a compound of the invention into a sample containing a cellular or more purified preparation  
5 containing a 5HT<sub>2C</sub> receptor.

**IN NEED OF PROPHYLAXIS OR TREATMENT** as used herein refers to a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from prophylaxis or treatment. This judgment is made based on a variety of  
10 factors that are in the realm of a caregiver's expertise, but that includes the knowledge that the individual or animal is ill, or will be ill, as the result of a disease, condition or disorder that is treatable by the compounds of the invention. In general, "in need of prophylaxis" refers to the judgment made by the caregiver that the individual will become ill. In this context, the compounds of the invention are used in a protective or preventive manner. However, "in need of treatment"  
15 refers to the judgment of the caregiver that the individual is already ill, therefore, the compounds of the present invention are used to alleviate, inhibit or ameliorate the disease, condition or disorder.

**INDIVIDUAL** as used herein refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

**PHARMACEUTICAL COMPOSITION** shall mean a composition comprising at least one  
20 active ingredient, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, and not limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.

**THERAPEUTICALLY EFFECTIVE AMOUNT** as used herein refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:

(1) Preventing the disease; for example, preventing a disease, condition or disorder in an  
30 individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease,

(2) Inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology),


and

(3) Ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).

5

### Compounds of the Present Invention

One aspect of the present invention pertains to certain substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives as represented by Formula (I):



10

wherein:

R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>2</sub> is C<sub>1-4</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or CH<sub>2</sub>OH; and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are each independently H, C<sub>1-4</sub> alkyl, amino, cyano, halogen, C<sub>1-4</sub> haloalkyl, nitro or OH; or

15

a pharmaceutically acceptable salt, hydrate and solvate thereof;

provided that when R<sub>2</sub> is C<sub>1-4</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-4</sub> alkyl, and CH<sub>2</sub>OH then R<sub>3</sub> and R<sub>6</sub> are not both hydrogen.

In some embodiments, when R<sub>1</sub> is H and R<sub>2</sub> is CH<sub>3</sub> then R<sub>3</sub>, R<sub>4</sub> and R<sub>6</sub> can not all be hydrogens and R<sub>5</sub> can not be hydrogen or *iso*-propyl.

20

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.


25

It is understood and appreciated that compounds of Formula (I) may have one or more chiral centers, and therefore can exist as enantiomers and/or diastereomers. The invention is understood to extend to and embrace all such enantiomers, diastereomers and mixtures thereof, including but not limited to racemates. Accordingly, one embodiment of the present invention pertains to compounds of Formula (I) and formulae used throughout this disclosure that are *R* enantiomers. Further, one embodiment of the present invention pertains to compounds of Formula (I) and formulae used throughout this disclosure that are *S* enantiomers. It is understood that

30

compounds of Formula (I) and formulae used throughout this disclosure are intended to represent all individual enantiomers and mixtures thereof, unless stated or shown otherwise.


In some embodiments of the present invention are compounds of Formula (I) wherein R<sub>1</sub> is H. In some embodiments, compounds can be represented by Formula (Ia) as illustrated below:



5

wherein each variable in Formula (Ia) has the same meaning as described herein, *supra* and *infra*.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>1</sub> is C<sub>1-8</sub> alkyl. In some embodiments R<sub>1</sub> is methyl. In some embodiments, compounds can be represented by Formula (Ib) as illustrated below:




10

wherein each variable in Formula (Ib) has the same meaning as described herein, *supra* and *infra*.

In some embodiments R<sub>1</sub> is ethyl. In some embodiments R<sub>1</sub> is *n*-propyl. In some embodiments R<sub>1</sub> is *iso*-propyl. In some embodiments R<sub>1</sub> is *n*-butyl.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>2</sub> is C<sub>1-4</sub> alkyl. In some embodiments R<sub>2</sub> is methyl. In some embodiments, compounds can be represented by Formula (Ic) as illustrated below:



wherein each variable in Formula (Ic) has the same meaning as described herein, *supra* and *infra*.

In further embodiments R<sub>2</sub> is ethyl. In some embodiments R<sub>2</sub> is *iso*-propyl. In some embodiments R<sub>2</sub> is *n*-butyl.

20

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_2$  is  $C_{1-4}$  haloalkyl. Examples of a  $C_{1-4}$  haloalkyl group include, but are not limited to,  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ ,  $CH_2CHF_2$ ,  $CH_2CH_2F$ ,  $CH_2CF_3$  and  $CF_2CF_3$ . In some embodiments  $R_2$  is  $-CF_3$ .


Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is H.

5 In some embodiments  $R_3$  is  $C_{1-4}$  alkyl. In some embodiments  $R_3$  is methyl (i.e.,  $-CH_3$ ).

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is amino.


Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is  
10 cyano.

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is halogen. In some embodiments  $R_3$  is a fluorine atom. In some embodiments, compounds can be represented by Formula (Ie) as illustrated below:



15 wherein each variable in Formula (Ie) has the same meaning as described herein, *supra* and *infra*. In some embodiments, compounds of the present invention are of Formula (Ie) and  $R_2$  is  $C_{1-4}$  alkyl; in further embodiments,  $R_2$  is  $CH_3$ .

In some embodiments,  $R_3$  is a chlorine atom. In some embodiments, compounds can be represented by Formula (Ig) as illustrated below:



20 wherein each variable in Formula (Ig) has the same meaning as described herein, *supra* and *infra*. In some embodiments, compounds of the present invention are of Formula (Ig) and  $R_2$  is  $C_{1-4}$  alkyl; in further embodiments,  $R_2$  is  $CH_3$ .

In some embodiments  $R_3$  is a bromine atom.

25 In some embodiments  $R_3$  is an iodine atom.



Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is  $C_{1-4}$  haloalkyl. In some embodiments  $R_3$  is  $CF_3$ .

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is nitro.

5 Some embodiments of the present invention are compounds of Formula (I) wherein  $R_3$  is -OH.


Some embodiments of the present invention are compounds of Formula (I) wherein  $R_4$  is H.

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_4$  is  $C_{1-4}$  alkyl. In some embodiments,  $R_4$  is methyl (i.e.,  $-CH_3$ ).

10 Some embodiments of the present invention are compounds of Formula (I) wherein  $R_4$  is amino.

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_4$  is cyano.


Some embodiments of the present invention are compounds of Formula (I) wherein  $R_4$  is halogen. In some embodiments  $R_4$  is a fluorine atom. In some embodiments, compounds can be represented by Formula (II) as illustrated below:



wherein each variable in Formula (II) has the same meaning as described herein, *supra* and *infra*.

In some embodiments, compounds of the present invention are of Formula (II) and  $R_2$  is  $C_{1-4}$  alkyl; in further embodiments,  $R_2$  is  $CH_3$ .

In some embodiments  $R_4$  is a chlorine atom. In some embodiments, compounds can be represented by Formula (Ik) as illustrated below:



wherein each variable in Formula (Ik) has the same meaning as described herein, *supra* and *infra*. In some embodiments, some embodiments of the present are of Formula (Ik) and R<sub>2</sub> is C<sub>1-4</sub> alkyl; in further embodiments, R<sub>2</sub> is CH<sub>3</sub>.

In some embodiments R<sub>4</sub> is a bromine atom.

5 In some embodiments R<sub>4</sub> is an iodine atom.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>4</sub> is C<sub>1-4</sub> haloalkyl. In some embodiments R<sub>4</sub> is CF<sub>3</sub>.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>4</sub> is nitro.

10 Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>4</sub> is -OH.


Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>5</sub> is H.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>5</sub> is C<sub>1-4</sub> alkyl. In some embodiments R<sub>5</sub> is methyl (i.e., -CH<sub>3</sub>).

15 Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>5</sub> is amino.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>5</sub> is cyano.

20 Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>5</sub> is halogen. In some embodiments R<sub>5</sub> is a fluorine atom. In some embodiments, compounds can be represented by Formula (Im) as illustrated below:




wherein each variable in Formula (Im) has the same meaning as described herein, *supra* and *infra*.

25 In some embodiments, compounds of the present invention are of Formula (Im) and R<sub>2</sub> is C<sub>1-4</sub> alkyl; in further embodiments, R<sub>2</sub> is CH<sub>3</sub>.

Some embodiments of the present invention are compounds of Formula (I) wherein R<sub>5</sub> is halogen. In some embodiments R<sub>5</sub> is a chlorine atom. In some embodiments, compounds can be represented by Formula (Io) as illustrated below:

18



wherein each variable in Formula **(Io)** has the same meaning as described herein, *supra* and *infra*.

In some embodiments, compounds of the present invention are of Formula **(Io)** and  $R_2$  is  $C_{1-4}$  alkyl; in further embodiments  $R_2$  is  $CH_3$ .

5 In some embodiments  $R_5$  is a bromine atom. In some embodiments  $R_5$  is an iodine atom.

Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_5$  is  $C_{1-4}$  haloalkyl. In some embodiments  $R_5$  is  $CF_3$ .

Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_5$  is nitro.

10 Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_5$  is -OH


Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_6$  is H.

Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_6$  is  $C_{1-4}$  alkyl. In some embodiments  $R_6$  is  $-CH_3$ .

15 Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_6$  is amino.

Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_6$  is cyano.


Some embodiments of the present invention are compounds of Formula **(I)** wherein  $R_6$  is halogen. In some embodiments  $R_6$  is a fluorine atom. In some embodiments, compounds can be represented by Formula **(Iq)** as illustrated below:



wherein each variable in Formula **(Iq)** has the same meaning as described herein, *supra* and *infra*.

25 In some embodiments, compounds of the present invention are of Formula **(Iq)** and  $R_2$  is  $C_{1-4}$  alkyl; in further embodiments  $R_2$  is  $CH_3$ .

In some embodiments  $R_6$  is a chlorine atom. In some embodiments, compounds can be represented by Formula (Is) as illustrated below:



wherein each variable in Formula (Is) has the same meaning as described herein, *supra* and *infra*.

- 5 In some embodiments, compounds of the present invention are of Formula (Is) and  $R_2$  is  $C_{1-4}$  alkyl in further embodiments,  $R_2$  is  $CH_3$ .

In some embodiments  $R_6$  is a bromine atom. In some embodiments  $R_6$  is an iodine atom.

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_6$  is  $C_{1-4}$  haloalkyl. In some embodiments  $R_6$  is  $CF_3$ .

- 10 Some embodiments of the present invention are compounds of Formula (I) wherein  $R_6$  is nitro.

Some embodiments of the present invention are compounds of Formula (I) wherein  $R_6$  is -OH.

- 15 In some embodiments, compounds of the present invention are of Formula (Ic) wherein  $R_1$  is H or  $C_{1-8}$  alkyl, and  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$  are each independently H or halogen.

In some embodiments, compounds of the present invention are of Formula (Ic) wherein  $R_1$  is H or  $CH_3$ , and  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$  are each independently H, F, Cl, or Br.


In some embodiments, compounds of the present invention are of Formula (Ic) wherein  $R_1$  is H, and  $R_3$  is H, F, Cl, or Br;  $R_4$  is H or Cl;  $R_5$  is H; and  $R_6$  is H or Cl.

- 20 In some embodiments, compounds of the present invention are of Formula (Ic) wherein  $R_1$  is  $CH_3$ , and  $R_3$  is H, F, Cl, or Br;  $R_4$  is H or Cl;  $R_5$  is H; and  $R_6$  is H or Cl.

This application is related to US Provisional Patent Application, Serial No. 60/479,280, which is incorporated by reference in its entirety.

- 25 Still further embodiments of the present invention are compounds of Formula (I) as shown in TABLE 2 below or a pharmaceutically acceptable salt, hydrate and solvate thereof:

TABLE 2



| R <sub>1</sub>  | R <sub>2</sub>  | R <sub>3</sub> | R <sub>4</sub> | R <sub>5</sub> | R <sub>6</sub> |
|-----------------|-----------------|----------------|----------------|----------------|----------------|
| H               | CH <sub>3</sub> | Cl             | H              | H              | Cl             |
| H               | CH <sub>3</sub> | Cl             | H              | Cl             | H              |
| H               | CH <sub>3</sub> | Cl             | Cl             | H              | H              |
| H               | CH <sub>3</sub> | Cl             | H              | H              | H              |
| H               | CH <sub>3</sub> | H              | H              | Cl             | Cl             |
| H               | CH <sub>3</sub> | H              | Cl             | H              | Cl             |
| H               | CH <sub>3</sub> | Cl             | H              | H              | Cl             |
| H               | CH <sub>3</sub> | H              | H              | H              | Cl             |
| H               | CH <sub>3</sub> | F              | H              | H              | Cl             |
| H               | CH <sub>3</sub> | F              | H              | Cl             | H              |
| H               | CH <sub>3</sub> | F              | Cl             | H              | H              |
| H               | CH <sub>3</sub> | F              | H              | H              | H              |
| H               | CH <sub>3</sub> | H              | H              | Cl             | F              |
| H               | CH <sub>3</sub> | H              | Cl             | H              | F              |
| H               | CH <sub>3</sub> | Cl             | H              | H              | F              |
| H               | CH <sub>3</sub> | H              | H              | H              | F              |
| H               | CH <sub>3</sub> | Br             | Cl             | H              | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | H              | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | Cl             | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | Cl             | H              | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | H              | H              |

| R <sub>1</sub>  | R <sub>2</sub>  | R <sub>3</sub> | R <sub>4</sub> | R <sub>5</sub> | R <sub>6</sub> |
|-----------------|-----------------|----------------|----------------|----------------|----------------|
| CH <sub>3</sub> | CH <sub>3</sub> | H              | H              | Cl             | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | H              | Cl             | H              | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | H              | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | H              | H              | H              | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | F              | H              | H              | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | F              | H              | Cl             | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | F              | Cl             | H              | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | F              | H              | H              | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | H              | H              | Cl             | F              |
| CH <sub>3</sub> | CH <sub>3</sub> | H              | Cl             | H              | F              |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | H              | F              |
| CH <sub>3</sub> | CH <sub>3</sub> | H              | H              | H              | F              |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | H              | Cl             |
| CH <sub>3</sub> | CH <sub>3</sub> | Cl             | H              | Cl             | H              |
| CH <sub>3</sub> | CH <sub>3</sub> | Br             | Cl             | H              | H              |

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: 6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; 6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; 8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and 8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: 6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; 6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; 8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; 8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: N-methyl-6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; N-methyl-6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; N-methyl-8-Chloro-9-fluoro-1-

methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; N-methyl-8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: (R)-6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (R)-6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (R)-8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (R)-8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and (R)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: (S)-6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (S)-6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (S)-8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (S)-8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and (S)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: (R)-N-methyl-6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (R)-N-methyl-6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (R)-N-methyl-8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (R)-N-methyl-8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and (R)-N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

Some embodiments of the present invention are compounds of Formula (I) selected from the group consisting of: (S)-N-methyl-6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (S)-N-methyl-6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (S)-N-methyl-8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; (S)-N-methyl-8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and (S)-N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate thereof.

At various places in the present specification substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C<sub>1-4</sub> alkyl" is specifically intended to individually and separately disclose methyl, ethyl, C<sub>3</sub> alkyl and C<sub>4</sub> alkyl.

## Methods and Use

One aspect of the present invention pertains to methods of modulating a 5HT<sub>2C</sub> receptor comprising contacting said receptor with a therapeutically effective amount or dose of a compound as described herein. Preferably, compounds of the present invention are agonists of the 5HT<sub>2C</sub> receptor.

Another aspect of the present invention pertains to methods of prophylaxis or treatment of a 5HT<sub>2C</sub> receptor associated disease in an individual comprising administering to the individual in need of such prophylaxis or treatment a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof. In some embodiments, the 5HT<sub>2C</sub> receptor associated disease is selected from the group consisting of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus and sleep apnea. In some embodiments, the individual is a mammal. Preferably, the mammal is a human.

In some embodiments, the 5HT<sub>2C</sub> receptor associated related disease is selected from the group consisting of depression, atypical depression, bipolar disorders, anxiety, anxiety disorders, obsessive-compulsive disorders, social phobias, panic states, attention deficit hyperactivity disorder, disruptive behavior disorders, impulse control disorders, borderline personality disorder, sleep disorders (e.g., sleep apnea), autism, seizure disorders, mutism, selective mutism, childhood anxiety disorders, sexual dysfunction in males (e.g., premature ejaculation and erectile difficulty or dysfunction), sexual dysfunction in females, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, dementia of aging, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, memory loss, chronic fatigue syndrome, drug and alcohol addiction, alcoholism, tobacco abuse, weight loss, obesity, bulimia, bulimia nervosa, anorexia nervosa, binge eating disorder, premenstrual tension, premenstrual syndrome (PMS or late luteal phase dysphoric disorder), post-traumatic syndrome, spinal cord injury, damage of the central nervous system (e.g., trauma, stroke, neurodegenerative diseases or toxic or infective disorders (e.g., thrombosis), gastrointestinal disorders (e.g., dysfunction of gastrointestinal motility), diabetes insipidus, and type II diabetes.

In some embodiments, the 5HT<sub>2C</sub> receptor associated disease is selected from the group consisting of high blood pressure, hypertension, high blood cholesterol, dyslipidemia, type II (non-insulin dependent) diabetes, insulin resistance, glucose intolerance, hyperinsulinemia, coronary heart disease, angina pectoris, congestive heart failure, stroke, gallstones, cholecystitis and



cholelithiasis, gout, osteoarthritis, obstructive sleep apnea and respiratory problems, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation), bladder control problems (such as stress incontinence), uric acid nephrolithiasis, psychological disorders (such as depression, eating disorders, distorted body image, and low self esteem).

In some embodiments, the 5HT<sub>2C</sub> receptor associated disease is selected from the group consisting of psychiatric symptoms and behaviors in individuals with eating disorders such as, but not limited to, anorexia nervosa and bulimia nervosa. Individuals with eating disorders often demonstrate social isolation. For example, anorexic individuals often present symptoms of being depressed, anxious, obsession, perfectionistic traits, and rigid cognitive styles as well as sexual disinterest. In addition to anorexia nervosa and bulimia nervosa, other eating disorders include, binge eating disorder (compulsive eating) and ED-NOS (i.e., eating disorders not otherwise specified - an official diagnosis). An individual diagnosed with ED-NOS possess atypical eating disorders including situations in which the individual meets all but a few of the criteria for a particular diagnosis. In essence, what the individual is doing with regard to food and weight is neither normal nor healthy.

In some embodiments, the 5HT<sub>2C</sub> receptor associated disease is selected from the group consisting of anorexia athletica (compulsive exercising), body dysmorphic disorder (bigorexia), infection-triggered auto immune subtype of anorexia in children, orthorexia nervosa, night-eating syndrome, nocturnal sleep-related eating disorder, rumination syndrome, gourmand syndrome, Prader-Willi syndrome, pica, and cyclic vomiting syndrome.

Another aspect of the present invention pertains to methods of decreasing food intake of an individual comprising administering to the individual a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof. In some embodiments, the individual is a mammal. Preferably, the mammal is a human. In further embodiments, the human has a body mass index of about 18.5 to about 45. In further embodiments, the human has a body mass index of about 25 to about 45. In further embodiments, the human has a body mass index of about 30 to about 45. In further embodiments, the human has a body mass index of about 35 to about 45.

Another aspect of the present invention pertains to methods of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof. In some embodiments, the individual is a mammal. Preferably, the mammal is a human. In further embodiments, the human has a body mass index of about 18.5 to about 45. In further embodiments,

the human has a body mass index of about 25 to about 45. In further embodiments, the human has a body mass index of about 30 to about 45. In further embodiments, the human has a body mass index of about 35 to about 45.

Another aspect of the present invention pertains to methods of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof. In some embodiments, the individual is a mammal. Preferably, the mammal is a human. In further embodiments, the human has a body mass index of about 18.5 to about 45. In further embodiments, the human has a body mass index of about 25 to about 45. In further  
5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045  
9050  
9055  
9060  
9065  
9070  
9075  
9080  
9085  
9090  
9095  
9100  
9105  
9110  
9115  
9120  
9125  
9130  
9135  
9140  
9145  
9150  
9155  
9160  
9165  
9170  
9175  
9180  
9185  
9190  
9195  
9200  
9205  
9210  
9215  
9220  
9225  
9230  
9235  
9240  
9245  
9250  
9255  
9260  
9265  
9270  
9275  
9280  
9285  
9290  
9295  
9300  
9305  
9310  
9315  
9320  
9325  
9330  
9335  
9340  
9345  
9350  
9355  
9360  
9365  
9370  
9375  
9380  
9385  
9390  
9395  
9400  
9405  
9410  
9415  
9420  
9425  
9430  
9435  
9440  
9445  
9450  
9455  
9460  
9465  
9470  
9475  
9480  
9485  
9490  
9495  
9500  
9505  
9510  
9515  
9520  
9525  
9530  
9535  
9540  
9545  
9550  
9555  
9560  
9565  
9570  
9575  
9580  
9585  
9590  
9595  
9600  
9605  
9610  
9615  
9620  
9625  
9630  
9635  
9640  
9645  
9650  
9655  
9660  
9665  
9670  
9675  
9680  
9685  
9690  
9695  
9700  
9705  
9710  
9715  
9720  
9725  
9730  
9735  
9740  
9745  
9750  
9755  
9760  
9765  
9770  
9775  
9780  
9785  
9790  
9795  
9800  
9805  
9810  
9815  
9820  
9825  
9830  
9835  
9840  
9845  
9850  
9855  
9860  
9865  
9870  
9875  
9880  
9885  
9890  
9895  
9900  
9905  
9910  
9915  
9920  
9925  
9930  
9935  
9940  
9945  
9950  
9955  
9960  
9965  
9970  
9975  
9980  
9985  
9990  
9995  
10000  
10005  
10010  
10015  
10020  
10025  
10030  
10035  
10040  
10045  
10050  
10055  
10060  
10065  
10070  
10075  
10080  
10085  
10090  
10095  
10100  
10105  
10110  
10115  
10120  
10125  
10130  
10135  
10140  
10145  
10150  
10155  
10160  
10165  
10170  
10175

neurodegenerative diseases, toxic CNS diseases or infective CNS diseases. In further embodiments, the damage to the central nervous system is by encephalitis or meningitis.

In some embodiments, the cardiovascular disorder is thrombosis.

In some embodiments, the gastrointestinal disorder is dysfunction of gastrointestinal  
5 motility.

Another aspect of the present invention pertains to methods of producing a pharmaceutical composition comprising admixing at least one compound of the present invention and at least one pharmaceutically acceptable carrier.

Another aspect of the present invention pertains to compounds, as described herein, for use  
10 in a method of treatment of the human or animal body by therapy.

Another aspect of the present invention pertains to compounds, as described herein, for use in a method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea of the human or animal body by therapy.

Another aspect of the present invention pertains to use of compounds, as described herein,  
15 for the manufacture of a medicament for use in the treatment or prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea.

Another aspect of the present invention pertains to the use of a compound of the present  
20 invention with agonist activity at the serotonin 5HT<sub>2C</sub> receptor for the treatment and/or prophylaxis of AD and AD related disorders. The compounds of the present invention can be used alone or in combination with another agent or agents (such as but not limited to AChE inhibitors) that are typically prescribed for AD.

## 25 **Combination Therapy - Prophylaxis and Treatment**

In the context of the present invention, a compound of Formula (I) or pharmaceutical composition thereof can be utilized for modulating the activity of the 5HT<sub>2C</sub> receptor associated diseases, conditions and/or disorders as described herein. Examples of modulating the activity of 5HT<sub>2C</sub> receptor associated diseases include the prophylaxis or treatment of obesity and/or  
30 overweight by decreasing food intake, inducing satiation (i.e., the feeling of fullness), controlling weight gain, decreasing body weight and/or affecting metabolism such that the recipient loses weight and/or maintains weight. Such compounds and pharmaceutical compositions can therefore be used in the context of disorders and/or diseases where weight gain is a component of a disease and/or disorder such as those listed herein. Furthermore, compounds and composition of the

present invention can be used for the prophylaxis and/or treatment of Alzheimer Disease, erectile dysfunction and other 5HT<sub>2C</sub> receptor associated diseases and/or disorders described herein.

While the compounds of the invention can be administered as the sole active pharmaceutical agent (i.e., mono-therapy), they can also be used in combination with other pharmaceutical agents (i.e., combination-therapy) for the treatment of the diseases/conditions/disorders described herein. Therefore, another aspect of the present invention includes methods of prophylaxis and/or treatment comprising administering to an individual in need of prophylaxis and/or treatment a therapeutically effective amount of a compound of the present invention, for example Formul (I), in combination with one or more additional pharmaceutical agent as described herein.

Suitable pharmaceutical agents that can be used in combination with the compounds of the present invention include anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, serotonin and norepinephrine reuptake inhibitors (for example, sibutramine), sympathomimetic agents,  $\beta_3$  adrenergic receptor agonists, dopamine agonists (for example, bromocriptine), melanocyte-stimulating hormone receptor analogs, cannabinoid 1 receptor antagonists [for example, SR141716: *N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide], melanin concentrating hormone antagonists, leptons (the OB protein), leptin analogues, leptin receptor agonists, galanin antagonists, lipase inhibitors (such as tetrahydrolipstatin, i.e., Orlistat), anorectic agents (such as a bombesin agonist), Neuropeptide-Y antagonists, thyromimetic agents, dehydroepiandrosterone or an analogue thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors (such as Axokine™ available from Regeneron Pharmaceuticals, Inc., Tarrytown, NY and Procter & Gamble Company, Cincinnati, OH), human agouti-related proteins (AGRP), ghrelin receptor antagonists, histamine 3 receptor antagonists or reverse agonists, neuromedin U receptor agonists, noradrenergic anorectic agents (for example, phentermine, mazindol and the like) and appetite suppressants (for example, bupropion).

Other anti-obesity agents, including the agents set forth *infra*, are well known, or will be readily apparent in light of the instant disclosure, to one of ordinary skill in the art.

In some embodiments, the anti-obesity agents are selected from the group consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine. In a further embodiment, compounds of the present invention and combination therapies are administered in conjunction with exercise and/or a sensible diet.

It will be understood that the scope of combination-therapy of the compounds of the present invention with other anti-obesity agents, anorectic agents, appetite suppressant and related agents is not limited to those listed above, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition useful for the treatment of overweight and obese individuals.

5 Other suitable pharmaceutical agents, in addition to anti-obesity agents, that can be used in combination with the compounds of the present invention include agents useful in the treatment of concomitant diseases. For example, individuals that are over weight or obese increase their risk of morbidity and mortality arising from concomitant diseases, such as, but not limited to, congestive heart failure, type II diabetes, atherosclerosis, dyslipidemia, hyperinsulinemia, hypertension, insulin resistance, hyperglycemia, retinopathy, nephropathy and neuropathy. Treatment for one or more of  
10 the diseases cited herein include the use of one or more pharmaceutical agents known in the art belonging to the classes of drugs referred to, but not limited to, the following: sulfonylureas, meglitinides, biguanides,  $\alpha$ -glucosidase inhibitors, peroxisome proliferators-activated receptor- $\gamma$  (i.e., PPAR- $\gamma$ ) agonists, insulin, insulin analogues, HMG-CoA reductase inhibitors, cholesterol-lowering drugs (for example, fibrates that include: fenofibrate, bezafibrate, gemfibrozil, clofibrate and the like; bile acid sequestrants which include: cholestyramine, colestipol and the like; and niacin), antiplatelet agents (for example, aspirin and adenosine diphosphate receptor antagonists that include: clopidogrel, ticlopidine and the like), angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and adiponectin. In accordance to one aspect of the present  
15 invention, a compound of the present can be used in combination with a pharmaceutical agent or agents belonging to one or more of the classes of drugs cited herein.  
20

It will be understood that the scope of combination-therapy of the compounds of the present invention with other pharmaceutical agents is not limited to those listed herein, *supra* or *infra*, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition  
25 useful for the treatment diseases, conditions or disorders that are linked to overweight and obese individuals.

Some embodiments of the present invention include methods of prophylaxis or treatment of a disease, disorder or condition as described herein comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effect amount or dose of a compound of the  
30 present invention in combination with at least one pharmaceutical agent selected from the group consisting of: sulfonylureas, meglitinides, biguanides,  $\alpha$ -glucosidase inhibitors, peroxisome proliferators-activated receptor- $\gamma$  (i.e., PPAR- $\gamma$ ) agonists, insulin, insulin analogues, HMG-CoA reductase inhibitors, cholesterol-lowering drugs (for example, fibrates that include: fenofibrate, bezafibrate, gemfibrozil, clofibrate and the like; bile acid sequestrants which include:

cholestyramine, colestipol and the like; and niacin), antiplatelet agents (for example, aspirin and adenosine diphosphate receptor antagonists that include: clopidogrel, ticlopidine and the like), angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and adiponectin. In some embodiments, methods of the present invention include compounds of the present invention and the pharmaceutical agents are administered separately. In further embodiments, compounds of the present invention and the pharmaceutical agents are administered together.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include  $\alpha$ -glucosidase inhibitors.  $\alpha$ -Glucosidase inhibitors belong to the class of drugs which competitively inhibit digestive enzymes such as  $\alpha$ -amylase, maltase,  $\alpha$ -dextrinase, sucrase, etc. in the pancreas and or small intestine. The reversible inhibition by  $\alpha$ -glucosidase inhibitors retard, diminish or otherwise reduce blood glucose levels by delaying the digestion of starch and sugars. Some representative examples of  $\alpha$ -glucosidase inhibitors include acarbose, N-(1,3-dihydroxy-2-propyl)valioline (generic name; voglibose), miglitol, and  $\alpha$ -glucosidase inhibitors known in the art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include sulfonylureas. The sulfonylureas (SU) are drugs which promote secretion of insulin from pancreatic  $\beta$  cells by transmitting signals of insulin secretion via SU receptors in the cell membranes. Examples of the sulfonylureas include glyburide, glipizide, glimepiride and other sulfonylureas known in the art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the meglitinides. The meglitinides are benzoic acid derivatives represent a novel class of insulin secretagogues. These agents target postprandial hyperglycemia and show comparable efficacy to sulfonylureas in reducing HbA<sub>1c</sub>. Examples of meglitinides include repaglinide, nateglinide and other meglitinides known in the art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the biguanides. The biguanides represent a class of drugs that stimulate anaerobic glycolysis, increase the sensitivity to insulin in the peripheral tissues, inhibit glucose absorption from the intestine, suppress of hepatic gluconeogenesis, and inhibit fatty acid oxidation. Examples of biguanides include phenformin, metformin, buformin, and biguanides known in the art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the  $\alpha$ -glucosidase inhibitors. The  $\alpha$ -glucosidase inhibitors competitively inhibit digestive enzymes such as  $\alpha$ -amylase, maltase,  $\alpha$ -dextrinase, sucrase, etc. in the pancreas and or small intestine. The reversible inhibition by  $\alpha$ -glucosidase inhibitors retard, diminish or

otherwise reduce blood glucose levels by delaying the digestion of starch and sugars. Examples of  $\alpha$ -glucosidase inhibitors include acarbose, N-(1,3-dihydroxy-2-propyl)valiolamine (generic name; voglibose), miglitol, and  $\alpha$ -glucosidase inhibitors known in the art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the peroxisome proliferators-activated receptor- $\gamma$  (i.e., PPAR- $\gamma$ ) agonists. The peroxisome proliferators-activated receptor- $\gamma$  agonists represent a class of compounds that activates the nuclear receptor PPAR- $\gamma$  and therefore regulate the transcription of insulin-responsive genes involved in the control of glucose production, transport and utilization. Agents in the class also facilitate the regulation of fatty acid metabolism. Examples of PPAR- $\gamma$  agonists include  
5      rosiglitazone, pioglitazone, tesaglitazar, netoglitazone, GW-409544, GW-501516 and PPAR- $\gamma$   
10     agonists known in the art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the HMG-CoA reductase inhibitors. The HMG-CoA reductase inhibitors are agents also referred to as Statin compounds that belong to a class of drugs that lower blood  
15     cholesterol levels by inhibiting hydroxymethylglutaryl CoA (HMG-CoA) reductase. HMG-CoA  
reductase is the rate-limiting enzyme in cholesterol biosynthesis. The statins lower serum LDL  
concentrations by upregulating the activity of LDL receptors and are responsible for clearing LDL  
from the blood. Some representative examples the statin compounds include rosuvastatin,  
pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin,  
20     rosuvastatin, pitavastatin, BMS's "superstatin", and HMG-CoA reductase inhibitors known in the  
art.

Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the angiotensin converting enzyme (ACE) inhibitors. The angiotensin  
converting enzyme inhibitors belong to the class of drugs that partially lower blood glucose levels as  
25     well as lowering blood pressure by inhibiting angiotensin converting enzymes. Examples of the  
angiotensin converting enzyme inhibitors include captopril, enalapril, alacepril, delapril; ramipril,  
lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat, fosinopril, moveltopril,  
perindopril, quinapril, spirapril, temocapril, trandolapril, and angiotensin converting enzyme  
inhibitors known in the art.

30     Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include the angiotensin II receptor antagonists. Angiotensin II receptor  
antagonists target the angiotensin II receptor subtype 1 (i.e., AT1) and demonstrate a beneficial  
effect on hypertension. Examples of angiotensin II receptor antagonists include losartan (and the  
potassium salt form), and angiotensin II receptor antagonists known in the art.

Other treatments for one or more of the diseases cited herein include the use of pharmaceutical agents known in the art belonging to the classes of drugs referred to, but not limited to, the following: amylin agonists (for example, pramlintide), insulin secretagogues (for example, GLP-1 agonists; exendin-4; insulinotropin (NN2211); dipeptyl peptidase inhibitors (for example, NVP-DPP-728), acyl CoA cholesterol acetyltransferase inhibitors (for example, Ezetimibe, eflucimibe, and like compounds), cholesterol absorption inhibitors (for example, ezetimibe, pamaqueside and like compounds), cholesterol ester transfer protein inhibitors (for example, CP-529414, JTT-705, CETi-1, and like compounds), microsomal triglyceride transfer protein inhibitors (for example, implitapide, and like compounds), cholesterol modulators (for example, NO-1886, and like compounds), bile acid modulators (for example, GT103-279 and like compounds) and squalene synthase inhibitors.

Squalene synthesis inhibitors belong to a class of drugs that lower blood cholesterol levels by inhibiting synthesis of squalene. Examples of the squalene synthesis inhibitors include (S)- $\alpha$ -[Bis[2,2-dimethyl-1-oxopropoxy)methoxy] phosphinyl]-3-phenoxybenzenebutanesulfonic acid, mono potassium salt (BMS-188494) and squalene synthesis inhibitors known in the art.

### Compositions of the Present Invention

According to a further aspect, the present invention also pertains to pharmaceutical compositions comprising one or more compounds of Formula (I) or any formulae disclosed herein, and one or more pharmaceutically acceptable carriers.

Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.

Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if necessary, forming the resulting mixture into a desired shape.

Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tableting lubricants, and disintegrants may be used in tablets and capsules for oral administration. Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants may be added to the liquid preparations. Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid



vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.

5 A compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically-acceptable carriers, outside those mentioned herein, are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20<sup>th</sup> Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro, A. R., et al.).

10 While it is possible that, for use in the prophylaxis or treatment, a compound of the invention may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.

The invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more  
15 pharmaceutically acceptable carriers thereof and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and  
20 intravenous) administration or in a form suitable for administration by inhalation, insufflation or by a transdermal patch. Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with a minimum of degradation of the drug. Typically, transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner. One of ordinary skill in the art will  
25 understand and appreciate the techniques appropriate for manufacturing a desired efficacious transdermal patch based upon the needs of the artisan.

The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical formulations and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions,  
30 suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective

amount of the active ingredient commensurate with the intended daily dosage range to be employed.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples  
5 of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate. The active ingredient may also be administered by injection as a composition  
10 wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.

Compounds of the present invention or a solvate or physiologically functional derivative thereof can be used as active ingredients in pharmaceutical compositions, specifically as 5HT<sub>2C</sub> receptor agonists. By the term "active ingredient" is defined in the context of a "pharmaceutical  
15 composition" and shall mean a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient" which would generally be recognized as providing no pharmaceutical benefit.

The dose when using the compounds of the present invention can vary within wide limits, and as is customary and is known to the physician, it is to be tailored to the individual conditions in  
20 each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the present invention. Representative doses of the present invention include, but not limited to, about 0.001 mg to about 5000 mg, about 0.001 to  
25 about 2500 mg, about 0.001 to about 1000 mg, 0.001 to about 500 mg, 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg, and about 0.001 mg to about 25 mg. Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4, doses. Depending on the individual and as deemed appropriate from the patient's physician or care-giver it may be necessary to deviate upward or  
30 downward from the doses described herein.

The amount of active ingredient, active salt or hydrate thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.

In general, one skilled in the art understands how to extrapolate in vivo data obtained in a model system, typically an animal model, to another, such as a human. Typically, animal models include, but are not limited to, rodent models. In some circumstances, these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors. Representative factors include, but are not limited to, the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on whether an acute or chronic disease state is being treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the Formula (I) as part of combination-therapy. The dosage regimen for treating a disease condition with the compounds and/or compositions of the present invention is selected in accordance with a variety of factors as cited above. Thus, the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations. The daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4, part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.

The compounds of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.

For preparing pharmaceutical compositions from the compounds of the present invention, the selection of a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desired shape and size.

5       The powders and tablets may contain varying percentage amounts of the active compound. A representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of this range are necessary. Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium  
10   carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral  
15   administration.

For preparing suppositories, a low melting wax, such as an admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

20       Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be  
25   formulated as solutions in aqueous polyethylene glycol solution. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable  
30   vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.

Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.

Administration to the respiratory tract may also be achieved by means of an aerosol

formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant. If the compounds of the Formula (I) or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler. Pharmaceutical forms for administration of the compounds of the Formula (I) as an aerosol can be prepared by processes well-known to the person skilled in the art. For their preparation, for example, solutions or dispersions of the compounds of the Formula (I) in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others, and, if appropriate, customary propellants, for example include carbon dioxide, CFC's, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.

Alternatively the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

The compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from

pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like, such as those pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977); incorporated herein by reference in its entirety.

The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.

Compounds of the present invention can be converted to "pro-drugs." The term "pro-drugs" refers to compounds that have been modified with specific chemical groups known in the art and when administered into an individual these groups undergo biotransformation to give the parent compound. Pro-drugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound. In general, the "pro-drug" approach is utilized to facilitate oral absorption. A thorough discussion is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.

Some embodiments of the present invention include a method of producing a pharmaceutical composition for "combination-therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein, at least one pharmaceutical agent as described herein and a pharmaceutically acceptable carrier.

In some embodiments the pharmaceutical agents is selected from the group consisting of: apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, serotonin and norepinephrine reuptake inhibitors (for example, sibutramine), sympathomimetic agents,  $\beta_3$  adrenergic receptor agonists, dopamine agonists (for example, bromocriptine), melanocyte-stimulating hormone receptor analogs, cannabinoid 1 receptor antagonists [for example, SR141716: *N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide], melanin concentrating hormone antagonists, leptons (the OB protein), leptin analogues, leptin receptor agonists, galanin antagonists,

lipase inhibitors (such as tetrahydrolipstatin, i.e., Orlistat), anorectic agents (such as a bombesin agonist), Neuropeptide-Y antagonists, thyromimetic agents, dehydroepiandrosterone or an analogue thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors (such as Axokine™), human agouti-related proteins (AGRP), ghrelin receptor antagonists, histamine 3 receptor antagonists or reverse agonists, neuromedin U receptor agonists, noradrenergic anorectic agents (for example, phentermine, mazindol and the like) and appetite suppressants (for example, bupropion). In further embodiments, the pharmaceutical agent is selected from the group consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine.

In some embodiments the pharmaceutical agents is selected from the group consisting of: sulfonylureas, meglitinides, biguanides,  $\alpha$ -glucosidase inhibitors, peroxisome proliferators-activated receptor- $\gamma$  (i.e., PPAR- $\gamma$ ) agonists, insulin, insulin analogues, HMG-CoA reductase inhibitors, cholesterol-lowering drugs (for example, fibrates that include: fenofibrate, bezafibrate, gemfibrozil, clofibrate and the like; bile acid sequestrants which include: cholestyramine, colestipol and the like; and niacin), antiplatelet agents (for example, aspirin and adenosine diphosphate receptor antagonists that include: clopidogrel, ticlopidine and the like), angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and adiponectin.

It is noted that when the 5HT<sub>2C</sub> receptor agonists are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of 5HT<sub>2C</sub> receptor agonists for the treatment of obesity in domestic animals (e.g., cats and dogs), and 5HT<sub>2C</sub> receptor agonists in other domestic animals where no disease or disorder is evident (e.g., food-oriented animals such as cows, chickens, fish, etc.). Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.


### Preparation of Compounds of the Invention

In the illustrated syntheses outlined below, the labeled substituents have the same identifications as set out in the definitions of the compounds of the present invention of Formula (I) and the Formulae of the subgenera as described herein.

Those of skill in the art will appreciate the wide variety of compounds of the present invention can be prepared according to Schemes I through V, *Infra*. One representative synthesis is set forth below in Scheme I, for when R<sub>2</sub> is methyl:



Scheme I



5

By utilizing, for example, an appropriately substituted 2-phenyl ethylamino Compound **A** having any of a wide variety of substituents  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  the corresponding substituted 1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound **H**) can be prepared. In a subsequent step, Compound **H** can be readily alkylated by, for example, treatment with excess formaldehyde or formaldehyde equivalent such as paraformaldehyde (for methylation) or a higher order aldehyde, followed by reduction with  $\text{NaBH}_3\text{CN}$  or similar reducing agent according to methodologies known in the art.


In addition, numerous synthetic transformations can be performed at different stages in the pathway illustrated in Scheme I to prepare additional compounds of Formula (I). For example, Compound **E** can be converted into a number of compounds of the invention including,  $R_2 = -\text{CH}_2\text{OH}$ . In this case, the double bond of Compound **E** can be hydroborated using methods known in the art, such as diborane, disiamylborane and the like, to give a primary alcohol after oxidative workup (i.e.,  $\text{H}_2\text{O}_2$ ). Either the N-protection can be removed to give desired compounds of the invention or the primary alcohol can be subsequently converted to an ether using methods known in the art such as, for example, the Williamson ether procedure, using an alkyl halide in the presence

20

of a base. In this example, the N-protection can be removed to give compounds of Formula (I) wherein  $R_2$  is the group  $\text{CH}_2\text{O}-\text{C}_{1-4}$  alkyl. Alternatively, the primary alcohol can be fluorinated using reagents known in the art, such as dialkylaminosulfur trifluorides and the like. Certain dialkylaminosulfur trifluorides include, but not limited to, bis(2-methoxyethyl)amino-sulfur trifluoride, (diethylamino)sulfur trifluoride, (dimethylamino)sulfur trifluoride, morpholinosulfur trifluoride and the like. Treatment with a fluorinating agent can give monofluoroalkyl compounds of Formula (I), wherein  $R_2$  is  $-\text{CH}_2\text{F}$ . In addition, the primary alcohol prepared from Compound E can be further oxidized to give the corresponding aldehyde and in a similar manner subsequently converted to difluoroalkyl compounds of Formula (I), wherein  $R_2$  is  $-\text{CHF}_2$ .


Reaction Scheme II is provided below showing these illustrative transformations and is not intended to be limiting:

Scheme II



Another representative synthetic pathway for the preparation of compounds of Formula (I) is set forth below in Reaction Scheme III:


Scheme III:




By utilizing, for example, an appropriately substituted 2-phenyl ethylamino Compound A having any of a wide variety of substituents  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  the corresponding 1-substituted-2,3,4,5-tetrahydro-1*H*-3-benzazepine [i.e., a compound of Formula (Ia)] can be prepared. Scheme III illustrates one general pathway for the introduction of  $R_2$  groups into the compounds of the present invention. Compound A is acylated with a carboxylic acid derivative using one of the many methods, such as one of the commonly known coupling agents, available to the artisan. A particularly useful method uses an acid chloride as described in the Examples, *Infra*. The carboxylic acid derivative is selected to possess a leaving group or a moiety that can be converted into a leaving group (i.e., Lg). The resulting Compound K is cyclized in the presence of a Lewis Acid, such as, for example, aluminum chloride. After reduction, compounds of the invention are obtained wherein  $R_1$  is H [i.e., a compound of Formula (Ia)].

One alternate synthetic approach that can be used to prepare compounds of the present invention utilizes Compound L (i.e.,  $R_2$  is H). In this method, the amide nitrogen is first alkylated (providing the  $R_1$  group, Compound N) or protected (i.e., Compound O) using any number of the methods known in the art. The  $R_2$  group is subsequently introduced via an alkylation reaction to provide Compounds P and Q respectively. Alkylation reactions can be conducted under basic conditions, for example, using DMF/NaH, and an alkylating agent of the formula  $R_2$ -Lg (wherein:  $R_2$  has the same meaning as described herein and Lg is a leaving group known in the art, such as, Cl, Br, I, OMs, OTs and the like). Examples of the alkylating agent include, but are not limited to,  $CH_3I$ ,  $CH_3OMs$ ,  $CH_3OTs$ ,  $CH_3CH_2I$ ,  $CF_3CH_2I$ ,  $CF_3I$ ,  $CH_3OCH_2Cl$  and the like. A representative alkylation example has been reported by Orito, K. and Matsuzaki, T. in *Tetrahedron*, **1980**, 36, 81, 1017-1021 and is incorporated herein by reference in its entirety. In the example when the nitrogen is protected (i.e., Compound Q), the protecting group is first removed and the amide reduced to provide compounds of the invention wherein  $R_1$  is H. In the example where the nitrogen is alkylated (i.e., Compound P), then the amide is merely reduced to provide compounds wherein  $R_1$  is alkyl. This method is illustrated in Schemes IV and V below:

Scheme IV





Those of skill in the art will appreciate that a wide variety of compounds of the present invention can be prepared according to Schemes I through V.

Protecting groups may be required for various functionality or functionalities during the synthesis of some of the compounds of the invention. Accordingly, representative protecting groups that are suitable for a wide variety of synthetic transformations are disclosed in Greene and Wuts, *Protective Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons, New York, 1999, the disclosure of which is incorporated herein by reference in its entirety.

As described herein, compounds of the present invention can exist in various forms, for example, enantiomers and racemates. It is understood that the optically active forms can be obtained by resolution of the racemates, separated by chiral chromatography or by asymmetric synthesis using methods known in the art to obtain enantiomers.

## Other Utilities

Another object of the present invention relates to radio-labeled compounds of Formula (I) that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the 5HT<sub>2C</sub> receptor in tissue samples, including human, and for identifying 5HT<sub>2C</sub> receptor ligands by inhibition binding of a radio-labeled compound. It is a further object of this invention to develop novel 5HT<sub>2C</sub> receptor assays of which comprise such radio-labeled compounds.

The present invention embraces isotopically-labeled compounds of Formula (I) and any subgenera herein, such as but not limited to, Formula (Ia) through Formula (Is). An "isotopically" or "radio-labeled" compounds are those which are identical to compounds disclosed herein, but for the fact that one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to <sup>2</sup>H (also written as D for deuterium), <sup>3</sup>H (also written as T for tritium), <sup>11</sup>C, <sup>13</sup>C, <sup>14</sup>C, <sup>13</sup>N, <sup>15</sup>N, <sup>15</sup>O, <sup>17</sup>O, <sup>18</sup>O, <sup>18</sup>F, <sup>35</sup>S, <sup>36</sup>Cl, <sup>82</sup>Br, <sup>75</sup>Br, <sup>76</sup>Br, <sup>77</sup>Br, <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I and <sup>131</sup>I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend

on the specific application of that radio-labeled compound. For example, for *in vitro* 5HT<sub>2C</sub> receptor labeling and competition assays, compounds that incorporate <sup>3</sup>H, <sup>14</sup>C, <sup>82</sup>Br, <sup>125</sup>I, <sup>131</sup>I, <sup>35</sup>S or will generally be most useful. For radio-imaging applications <sup>11</sup>C, <sup>18</sup>F, <sup>125</sup>I, <sup>123</sup>I, <sup>124</sup>I, <sup>131</sup>I, <sup>75</sup>Br, <sup>76</sup>Br or <sup>77</sup>Br will generally be most useful.

- 5           It is understood that a "radio-labeled " or "labeled compound" is a compound of Formula (I) that has incorporated at least one radionuclide; in some embodiments the radionuclide is selected from the group consisting of <sup>3</sup>H, <sup>14</sup>C, <sup>125</sup>I, <sup>35</sup>S and <sup>82</sup>Br.

Certain isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays. In some embodiments the radionuclide <sup>3</sup>H and/or <sup>14</sup>C  
10       isotopes are useful in these studies. Further, substitution with heavier isotopes such as deuterium (i.e., <sup>2</sup>H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased *in vivo* half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes *supra* and Examples *infra*, by  
15       substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Other synthetic methods that are useful are discussed *infra*. Moreover, it should be understood that all of the atoms represented in the compounds of the invention can be either the most commonly occurring isotope of such atoms or the more scarce radio-isotope or nonradio-active isotope.

Synthetic methods for incorporating radio-isotopes into organic compounds are applicable  
20       to compounds of the invention and are well known in the art. These synthetic methods, for example, incorporating activity levels of tritium into target molecules, are as follows:

A. Catalytic Reduction with Tritium Gas - This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors.

B. Reduction with Sodium Borohydride [<sup>3</sup>H] - This procedure is rather inexpensive and  
25       requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like.

C. Reduction with Lithium Aluminum Hydride [<sup>3</sup>H] - This procedure offers products at almost theoretical specific activities. It also requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like.

30       D. Tritium Gas Exposure Labeling - This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst.

E. N-Methylation using Methyl Iodide [<sup>3</sup>H] - This procedure is usually employed to prepare O-methyl or N-methyl (<sup>3</sup>H) products by treating appropriate precursors with high specific activity methyl iodide (<sup>3</sup>H). This method in general allows for higher specific activity, such as for

example, about 70-90 Ci/mmol.

Synthetic methods for incorporating activity levels of  $^{125}\text{I}$  into target molecules include:

5       **A.** Sandmeyer and like reactions – This procedure transforms an aryl or heteroaryl amine into a diazonium salt, such as a tetrafluoroborate salt, and subsequently to  $^{125}\text{I}$  labeled compound using  $\text{Na}^{125}\text{I}$ . A represented procedure was reported by Zhu, D.-G. and co-workers in *J. Org. Chem.* **2002**, 67, 943-948.

**B.** Ortho  $^{125}\text{I}$  iodination of phenols – This procedure allows for the incorporation of  $^{125}\text{I}$  at the ortho position of a phenol as reported by Collier, T. L. and co-workers in *J. Labeled Compd Radiopharm.* **1999**, 42, S264-S266.

10       **C.** Aryl and heteroaryl bromide exchange with  $^{125}\text{I}$  – This method is generally a two step process. The first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e.  $\text{Pd}(\text{Ph}_3\text{P})_4$ ] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g.,  $(\text{CH}_3)_3\text{SnSn}(\text{CH}_3)_3$ ]. A represented procedure was reported by Bas, M.-D. and co-workers in *J.*  
15 *Labeled Compd Radiopharm.* **2001**, 44, S280-S282.

      A radio-labeled  $5\text{HT}_{2\text{C}}$  receptor compound of Formula (I) can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the “radio-labeled compound of Formula (I)” to the  $5\text{HT}_{2\text{C}}$  receptor. Accordingly, the ability of a test compound to compete with  
20 the “radio-labeled compound of Formula (I)” for the binding to the  $5\text{HT}_{2\text{C}}$  receptor directly correlates to its binding affinity.

      The labeled compounds of the present invention bind to the  $5\text{HT}_{2\text{C}}$  receptor. In one embodiment the labeled compound has an  $\text{IC}_{50}$  less than about 500  $\mu\text{M}$ , in another embodiment the labeled compound has an  $\text{IC}_{50}$  less than about 100  $\mu\text{M}$ , in yet another embodiment the labeled  
25 compound has an  $\text{IC}_{50}$  less than about 10  $\mu\text{M}$ , in yet another embodiment the labeled compound has an  $\text{IC}_{50}$  less than about 1  $\mu\text{M}$ , and in still yet another embodiment the labeled inhibitor has an  $\text{IC}_{50}$  less than about 0.1  $\mu\text{M}$ .

      Other uses of the disclosed receptors and methods will become apparent to those in the art based upon, inter alia, a review of this disclosure.

30       As will be recognized, the steps of the methods of the present invention need not be performed any particular number of times or in any particular sequence. Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are intended to be illustrative and not intended to be limiting.

**EXAMPLES****Example 1****Intracellular IP<sub>3</sub> Accumulation Assay:**

5 HEK293 cells were transfected in 15cm sterile dishes with or without (control) 16ug of human 5HT<sub>2C</sub> receptor cDNA [for example see, Saltzman, A. G., et al. *Biochem. Biophys. Res. Commun.* 181, 1469-1478 (1991)] using 25ul of lipofectamine. Cells were then incubated for 3-4 hours at 37°C/5%CO<sub>2</sub> and then transfection media was removed and replaced with 100ul of DMEM. Cells were then plated onto 100cm sterile dishes. The next day cells were plated into 96  
10 well PDL microtiter plates at a density of 55K/0.2ml. Six hours latter, media was exchanged with [<sup>3</sup>H]inositol (0.25 uCi/well) in inositol free DMEM and plates were incubated at 37°C/5%CO<sub>2</sub> overnight. The next day, wells were aspirated and 200ul of DMEM containing test compound, 10uM pargyline, and 10mM LiCl was added to appropriate wells. Plates were then incubated at 37°C/5%CO<sub>2</sub> for three hours followed aspiration and by addition of fresh ice cold stop solution (1M  
15 KOH, 19mM Na-borate, 3.8 mM EDTA) to each well. Plates were kept on ice for 5-10 min and the wells were neutralized by addition of 200ul of fresh ice cold neutralization solution (7.5% HCl). Plates were then frozen until further processing is desired. The lysate was then transferred into 1.5 ml Eppendorf tubes and 1 ml of chloroform/methanol (1:2) was added/tube. The solution was vortexed for 15 seconds and the upper phase was applied to a Biorad AG1-X8™ anion exchange  
20 resin (100-200 mesh). First, the resin was washed with water at 1:1.25 W/V and 0.9 ml of upper phase was loaded onto the column. The column was then washed with 10 ml of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60mM Na-formate. The inositol tris phosphates were eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/ 1 M ammonium formate. The columns were regenerated by washing with 10 ml of 0.1 M formic  
25 acid/3M ammonium formate and rinsed twice with dd H<sub>2</sub>O and stored at 4°C in water.

The biological activities in the IP Accumulation Assay for several representative compounds are shown in **Table 3** below:


**Table 3**

| Compound No. | 5HT <sub>2C</sub> (IC <sub>50</sub> ) |
|--------------|---------------------------------------|
|              | IP Accumulation Assay (nM)            |
| 1            | 11.7                                  |
| 3            | 24.5                                  |

30 The majority of the compounds of the Examples showed activities in the IP Accumulation Assay in the range between about 11 nM and about 5 μM.

**Example 2****Inhibition of food intake in food-deprived rats**

Male Sprague-Dawley rats (250-350g) are deprived of food overnight prior to testing. Prior to food deprivation, the animals are weighed and separated into treatment groups in order to balance groups according to body weight. On the test day, animals are placed into individual cages (no bedding) at 9:00am with free access to water. At 10:00am, animals are injected with test compound (p.o., i.p., or s.c.) and then presented with a pre-weighed amount of food in a dish either 60 min (p.o.) or 30 min (i.p. and s.c.) after drug administration. Food consumption over different time points is determined by weighing the food cup at 1, 2, 4, and 6 hr after the food is presented. Thus, food consumption is measured at 2, 3, 5, and 7 hr post-injection in p.o. studies, and at 1.5; 2.5, 4.5, and 6.5 hr post-injection in i.p. and s.c. studies.

**Example 3****Syntheses of Selected Compounds of the Invention****Example 3.1: Preparation of (R,S) 6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Also referred to herein as Compound 1).****Step 1: Preparation of 2-chloro-N-[2-(2,4-dichlorophenyl)ethyl]propionamide.**

A solution of 2,4-dichlorophenethylamine (1.0 g, 5.3 mmol) in dichloromethane (20 mL) was treated with diisopropylethylamine (0.82 g, 6.3 mmol) and 2-chloropropionylchloride (0.67 mL, 5.3 mmol) sequentially, and stirred at 20°C for 4 hours. The mixture was diluted with dichloromethane (50 mL), washed with 10% aqueous HCl, brine (20 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated, resulting in 1.5 g of the desired product as a brown oil. MS calculated for C<sub>11</sub>H<sub>12</sub>Cl<sub>3</sub>NO+H: 280, observed: 280.


**Step 2: Preparation of 6,8-dichloro-1-methyl-2-oxo-2,3,5-trihydro-1H-3-benzazepine.**

Neat 2-Chloro-N-[2-(2,4-dichlorophenyl)ethyl]propionamide (2.5 g, 9.1 mmol) and AlCl<sub>3</sub> (3.6 g, 27 mmol) were heated at 150°C for 18 hours while stirring. The product mixture was quenched with water (10 mL), diluted with dichloromethane (100 mL), the organic phase separated, washed with brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated, resulting in 1.9 g of a brown oil. MS calculated for C<sub>11</sub>H<sub>11</sub>Cl<sub>2</sub>NO+H: 244, observed: 244.




**Step 3: Preparation of 6,8-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

A solution of 6,8-Dichloro-1-methyl-2-oxo-2,3,5-trihydro-1H-3-benzazepine (1.9 g, 7.8 mmol) in tetrahydrofuran (50 mL) was treated with 1.0 M borane in THF (20.0 mL, 20.0 mmol), and stirred at 20°C for 5 hours. The mixture was quenched with methanol (10 mL), acidified with concentrated HCl (0.2 mL), azeotroped with methanol (3 x 100 mL) and concentrated. Flash chromatography (5% methanol in dichloromethane) resulted in 1.0 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.20 (s, 1 H), 6.90 (s, 1 H), 4.30 (bs, 1 H), 3.92 (m, 1 H), 3.51 (m, 1 H), 3.37 (m, 2 H), 3.03 (m, 1 H), 2.77 (m, 2 H), 1.31 (d, J=8 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>13</sub>Cl<sub>2</sub>N+H: 230, observed: 230.

**Example 3.2: Preparation of (R,S) 6-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 2).**

Compound 2 was prepared utilizing a similar procedure as described for the preparation of Compound 1. (R,S) 6-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was obtained from 2-chlorophenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.17 (d, J=8 Hz, 1 H), 6.93 (m, 2 H), 3.97 (bs, 1 H), 3.79 (m, 1 H), 3.3-3.1 (m, 3 H), 2.95 (d, J=11 Hz, 1 H), 2.8-2.6 (m, 2 H), 1.3 (d, J=8 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>14</sub>ClN+H: 196, observed: 196.

**Example 3.3: Preparation of (R,S) 8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 3).****Step 1: Preparation of N-Trifluoroacetyl-8-chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**


A solution of N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2.5 g, 8.5 mmol) in 1,2-dichloroethane (15 mL) was treated with Selectfluor (3.9 g, 11 mmol), trifluoromethanesulfonic acid (8 mL, 90 mmol) and stirred 60 hours at 75°C. The product mixture was poured into water (200 mL), extracted with EtOAc (200 mL), the organic phase washed with saturated aqueous NaHCO<sub>3</sub> (2 x 100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated.

The crude product was purified by flash chromatography (6 % EtOAc in hexane, silica) resulting in 0.6 g of a white solid. MS calculated for  $C_{13}H_{12}ClF_4NO+H$ : 310, observed: 310.

**Step 2: Preparation of 8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**


5 A solution of N-trifluoroacetyl-8-chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (160 mg, 0.22 mmol) in methanol (3 mL) was treated with 15% aqueous NaOH (2 mL), and stirred for 3.5 hours at 25°C. The product mixture was concentrated, extracted 3 times with  $CH_2Cl_2$  (5 mL), dried with  $Na_2SO_4$  and concentrated to give 93 mg of a clear oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.06 (dd, J=8, 8 Hz, 1 H), 6.75 (d, J=8 Hz, 1 H), 3.58 (m, 1 H), 3.25-3.15 (m, 10 3 H), 2.93 (d, J=13 Hz, 1 H) 2.75-2.60 (m, 3H), 1.96 (bs, 1 H), 1.33 (d, J=8 Hz, 3 H). MS calculated for  $C_{11}H_{13}ClFN+H$ : 214, observed: 214.

**Example 3.4: Preparation of (R,S) 8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 4).**



15 Compound 4 was prepared utilizing a similar procedure as described herein for the preparation of Compound 1. (R,S) 8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was obtained from 3,4-dichlorophenethylamine as a colorless oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.40 (d, J=8 Hz, 1 H), 7.16 (d, J=8 Hz, 1 H), 4.17 (m, 1 H), 3.55 (m, 2 H), 3.5-3.3 (m, 2 H), 3.2-3.0 (m, 20 2 H), 1.43 (d, J=7 Hz, 3 H). MS calculated for  $C_{11}H_{13}Cl_2N+H$ : 230, observed: 230.

**Example 3.5: Preparation of (S)-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 5).**



25 **Step 1: Preparation of (S)-N-Trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

(S)-N-Trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was prepared from (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine utilizing a similar procedure as described herein for the preparation of Compound 7 (one exception is that the resolution step was 30 performed using D-tartaric acid).  $^1H$  NMR (400 MHz,  $CDCl_3$ , mixture of rotamers)  $\delta$  7.27 (m, 1H),

6.96 (m, 1H), 4.26 (bm, 0.6H), 4.19-4.03 (m, 1.7H), 3.92-3.87 (m, 0.8H) 3.75-3.69 (m, 0.8H), 3.47-3.22 (m, 2H), 2.91 (m, 1H), 1.28-1.25 (m, 3H). MS calculated for  $C_{13}H_{13}ClF_3NO+H$ : 292, observed: 292.


**Step 2: Preparation of (S)-N-Trifluoroacetyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

A solution of (S)-N-Trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.62g, 2.1 mmol) in dichloromethane (10 mL) was treated with N-chlorosuccinimide (0.284 g, 2.1 mmol) and trifluoromethanesulfonic acid (0.639 g, 4.2 mmol). The reaction was stirred for 16h at 20°C, diluted with water (20 mL) and extracted with dichloromethane (25 mL). The organics were dried with  $MgSO_4$ , filtered and concentrated. HPLC purification was done to provide 0.078 g of a white solid.  $^1H$  NMR (400 MHz,  $CDCl_3$ , mixture of rotamers)  $\delta$  7.32-7.25 (m, 1H), 6.97-6.93 (m, 1H), 4.27-4.24 (m, 0.6H), 4.19-4.13 (m, 1H), 4.08-4.01 (m, 1H), 3.91-3.86 (0.8H, m), 3.74-3.69 (m, 0.8H), 3.45-3.37 (m, 1H), 3.31-3.21 (m, 1H), 2.96-2.80 (m, 1H), 1.28-1.22 (m, 3H). MS calculated for  $C_{13}H_{12}Cl_2F_3NO+H$ : 326, observed: 326.

**Step 3: Preparation of (S)-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

A solution of (S)-N-trifluoroacetyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.270 g, 1.2 mmol) in methanol (10 mL) was treated with 15% aqueous NaOH (10 mL), and stirred for 3.5 hours at 25°C. The product mixture was concentrated, extracted 3 times with  $CH_2Cl_2$  (25 mL), dried with  $Na_2SO_4$  and concentrated to give 0.270 g of a clear oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.40 (d,  $J=8$  Hz, 1 H), 7.16 (d,  $J=8$  Hz, 1 H), 4.17 (m, 1 H), 3.55 (m, 2 H), 3.5-3.3 (m, 2 H), 3.2-3.0 (m, 2 H), 1.43 (d,  $J=7$  Hz, 3 H). MS calculated for  $C_{11}H_{13}Cl_2N+H$ : 230, observed: 230.

**Example 3.6: Preparation of (S)-8-chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 6).**



**Step 1: Preparation of (S)-N-Trifluoroacetyl-8-chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**


A solution of (S)-N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2.5 g, 8.5 mmol) in 1,2-dichloroethane (15 mL) was treated with Selectfluor (3.9 g, 11 mmol), trifluoromethanesulfonic acid (8 mL, 90 mmol) and stirred 60 hours at 75°C. The product mixture

was poured into water (200 mL), extracted with EtOAc (200 mL), the organic phase washed with saturated aqueous NaHCO<sub>3</sub> (2 x 100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by flash chromatography (6 % EtOAc in hexane, silica) resulting in 0.6 g of a white solid. MS calculated for C<sub>13</sub>H<sub>12</sub>ClF<sub>4</sub>NO+H: 310, observed: 310.

5           **Step 2: Preparation of (S)-8-chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

A solution of (S)-N-trifluoroacetyl-8-chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (160 mg, 0.22 mmol) in methanol (3 mL) was treated with 15% aqueous NaOH (2 mL), and stirred for 3.5 hours at 25°C. The product mixture was concentrated, extracted 3 times  
10 with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 93 mg of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.06 (dd, J=8, 8 Hz, 1 H), 6.75 (d, J=8 Hz, 1 H), 3.58 (m, 1 H), 3.25-3.15 (m, 3 H), 2.93 (d, J=13 Hz, 1 H) 2.75-2.60 (m, 3H), 1.96 (bs, 1 H), 1.33 (d, J=8 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>13</sub>ClFN+H: 214, observed: 214.

15           **Example 3.7: Preparation of (R)-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 7).**



**Step 1: Preparation of 2-(4-chlorophenyl)ethyl-N-2-chloropropionamide**

To a 1-liter, 3-necked round bottom flask under argon balloon equipped with reflux  
20 condenser and addition funnel, were added sequentially 2-(4-chlorophenyl) ethylamine (30 g, 193 mmol), 400 mL acetonitrile, triethylamine (19.5 g, 193 mmol) and 80 mL acetonitrile. The clear colorless solution was stirred and cooled to 0°C. 2-Chloropropionyl chloride (24.5 g, 193 mmol, distilled) in 5 mL acetonitrile was slowly added over 20 minutes to evolution of white gas, formation of white precipitate, and color change of reaction mixture to slight yellow. An additional  
25 10 mL of acetonitrile was used to rinse the addition funnel. The mixture was stirred at 0°C for 30 minutes and then warmed to room temperature and stirred vigorously for an additional one hour. The yellow reaction mixture was concentrated on the rotary evaporator to a solid containing triethylamine hydrochloride (76.36 grams). This material was taken up in 100 mL ethylacetate and 200 mL water, and stirred vigorously. The layers were separated and the aqueous layer was  
30 extracted with an additional 100 mL ethylacetate. The combined organic layers were washed twice with 25 mL of saturated brine, dried over magnesium sulfate, filtered, and concentrated to a light tan solid (41.6 grams, 88 %). TLC in ethylacetate-hexane, 8:2 showed a major spot two-thirds of

the way up the plate and a small spot at the baseline. Baseline spot was removed as follows: This material was taken up in 40 mL of ethylacetate and hexane was added until the solution became cloudy. Cooling to 0°C produced a white crystalline solid (40.2 grams, 85 % yield). The product is a known compound (Hasan et al., *Indian J. Chem.*, **1971**, 9(9), 1022) with CAS Registry No.

- 5 34164-14-2. LC/MS gave product 2.45 minute; 246.1  $M^+ + H^+$ .  $^1H$  NMR ( $CDCl_3$ ):  $\delta$  7.2 (dd, 4H, Ar), 6.7 (br s, 1H, NH), 4.38 (q, 1H,  $CHCH_3$ ), 3.5 (q, 2H,  $ArCH_2CH_2NH$ ), 2.8 (t, 2H,  $ArCH_2$ ), 1.7 (d, 3H,  $CH_3$ ).  $^{13}C$  NMR ( $CDCl_3$ ): 169 (1C, C=O), 136 (1C, Ar-Cl), 132 (1C, Ar), 130 (2C, Ar), 128 (2C, Ar), 56 (1C,  $CHCl$ ), 40 (1C, CHN), 34 (1C,  $CHAr$ ), 22 (1C,  $CH_3$ ).

**Step2: Preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one.**

- 10 2-(4-Chlorophenyl)ethyl-N-2-chloropropionamide (10 g, 40.6 mmol) and aluminum chloride (16 g, 119.9 mmol) were added to a clean dry 100 mL round bottom flask equipped with an argon balloon, stirring apparatus, and heating apparatus. The white solid melted to a tan oil with bubbling at 91 °C. (Note: if impure starting materials are used, a black tar can result but clean product can still be isolated). The mixture was heated and stirred at 150°C for 12 hours. The
- 15 reaction can be followed by LC/MS with the starting material at 2.45 minutes (246.1  $M^+ + H^+$ ), the product at 2.24 minutes (209.6  $M^+ + H^+$ ) on a 5 minute reaction time from 5-95% w/ 0.01 % TFA in water/MeCN(50:50). After cooling to room temperature, the reaction mixture was quenched with slow addition of 10 mL of MeOH followed by 5 mL of 5 % HCl in water and 5 mL of ethyl acetate. After separation of the resulting layers, the aqueous layer was extracted a second time with 10 mL
- 20 of ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to a tan solid (6.78 grams, 80 % yield). LC/MS showed one peak, at 2.2 min and 209.6 MI. This material was taken up in ethyl acetate, filtered through celite and Kieselgel 60 (0.5 inch plug on a 60 mL Buchner funnel) and the filtrate was recrystallized from hexane/ethyl acetate to give final product (4.61 grams, 54 % yield).  $^1H$  NMR ( $CDCl_3$ ):  $\delta$  7.3-7.1 (m, 3H, Ar), 5.6 (br s,
- 25 1H, NH), 4.23 (q, 1H,  $CHCH_3$ ), 3.8 (m, 1H,  $ArCH_2CH_2NH$ ), 3.49 (m, 1H,  $ArCH_2CH_2NH$ ), 3.48 (m, 1H,  $ArCH_2CH_2NH$ ), 3.05 (m, 1H,  $ArCH_2CH_2NH$ ), 1.6 (d, 3H,  $CH_2$ ).  $^{13}C$  NMR ( $CDCl_3$ ): 178 (1C, C=O), 139 (1C, Ar), 135 (1C, Ar), 130, 129 (2C, Ar), 126 (2C, Ar), 42 (1C, C), 40 (1C, CHN), 33 (1C,  $CHAr$ ), 14 (1C,  $CH_3$ ).

**Step 3: Preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

- 30 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one (150 mg, 0.716 mmol, purified by HPLC or recrystallization) was added to a 50 mL round bottom flask with 2M borane-tetrahydrofuran solution (2 mL, 2.15 mmol). The mixture was stirred 10 hours at room temperature under an argon balloon. LC/MS showed the desired product as the major peak with approximately 5 % of starting material still present. The reaction mixture was quenched with 5 mL methanol and

the solvents were removed on the rotary evaporator. This procedure was repeated with methanol addition and evaporation. The mixture was evaporated on the rotary evaporator followed by 2 hours in vacuo to give the product as a white solid (117 mg, 70 % yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.2 (br s, 1H), 9.8 (br s, 1H), 7.14 (dd, 1H, J = 2, 8 Hz), 7.11 (d, 1H, J = 2 Hz), 7.03 (d, 1H, J = 8 Hz), 3.6 (m, 2H), 3.5 (m, 2H), 2.8-3.0 (m, 3 H), 1.5 (d, 3H, J = 7 Hz). LC/MS: 1.41 minute, 196.1 M + H<sup>+</sup> and 139 major fragment.

**Step 4: Preparation of L-(+)-tartaric acid salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

To a clean, dry 50 mL round bottom flask were added 11.5 g (0.06 mol) of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine to 2.23 g (0.015 mol) of L-(+)-tartaric acid. The suspension was diluted with 56 g of tert-butanol and 6.5 mL of H<sub>2</sub>O. The mixture was heated to reflux (75-78°C) and stirred for 10 min to obtain a colorless solution. The solution was slowly cooled down to room temperature (during 1h) and stirred for 3h at room temperature. The suspension was filtered and the residue was washed twice with acetone (10 mL). The product was dried under reduced pressure (50 mbar) at 60 °C to yield 6.3 g of the tartrate salt (ee = 80). This tartrate salt was added to 56 g of tert-butanol and 6.5 mL of H<sub>2</sub>O. The resulting suspension was heated to reflux and 1 to 2g of H<sub>2</sub>O was added to obtain a colorless solution. The solution was slowly cooled down to room temperature (over the course of 1h) and stirred for 3h at room temperature. The suspension was filtered and the residue was washed twice with acetone (10 mL). The product was dried under reduced pressure (50 mbar) at 60°C to produce 4.9 g (48 % yield) of product (ee >98.9).

**Step 5: Conversion of Salt to Free Amine - (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

The L-tartaric acid salt of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (300 mg, 0.87 mmol) was added to a 25 mL round bottom flask with 50% sodium hydroxide solution (114 μL, 2.17 mmol) with an added 2 mL of water. The mixture was stirred 3 minutes at room temperature. The solution was extracted with methylene chloride (5 mL) twice. The combined organic extracts were washed with water (5 mL) and evaporated to dryness on the pump to afford free amine (220 mg crude weight). LC/MS 196 (M+H).

**Step 6: Preparation of (R)-N-Trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**


A solution of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride salt (1.0 g, 4.31mmol) in dichloromethane (50 mL) at 0°C was treated with pyridine (1.0 mL) and trifluoroacetic anhydride (1.35 g, 6.46 mmole). This was warmed to 20°C, stirred for 3h and

diluted with 1M HCl (25 mL). This was extracted with dichloromethane (2 x 50 mL) and the organics dried with MgSO<sub>4</sub>, filtered and concentrated to give 1.17 g as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.27 (m, 1H), 6.96 (m, 1H), 4.26 (bm, 0.6H), 4.19-4.03 (m, 1.7H), 3.92-3.87 (m, 0.8H), 3.75-3.69 (m, 0.8H), 3.47-3.22 (m, 2H), 2.91 (m, 1H), 1.28-1.25 (m, 3H). MS calculated for C<sub>13</sub>H<sub>13</sub>ClF<sub>3</sub>NO+H: 292, observed: 292.

**Step 7: (R)-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**

Compound 7 was prepared from (R)-N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine utilizing a similar two step procedure as described herein for the preparation of Compound 5. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40 (d, J=8 Hz, 1 H), 7.16 (d, J=8 Hz, 1 H), 4.17 (m, 1 H), 3.55 (m, 2 H), 3.5-3.3 (m, 2 H), 3.2-3.0 (m, 2 H), 1.43 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>13</sub>Cl<sub>2</sub>N+H: 230, observed: 230.

**Example 3.8: Preparation of (S)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 8).**




**Step 1: - Preparation of (S)-N-Trifluoroacetyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

A solution of (S)-N-Trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.875g, 3.0 mmol) in dichloroethane (7 mL) was treated with N-bromosuccinimide (0.284 g, 2.1 mmol) and trifluoromethanesulfonic acid (0.639 g, 4.2 mmol). The reaction was stirred for 16h at 75°C, diluted with ethyl acetate (20 mL) and extracted with water (2x10 mL). The organics were dried with MgSO<sub>4</sub>, filtered and concentrated. Flash chromatography (5 % EtOAc in hexanes, silica) resulted in 0.13 g of a clear oil. MS calculated for C<sub>13</sub>H<sub>12</sub>BrClF<sub>3</sub>NO+H: 370, observed: 370.

**Step 2: Preparation of (S)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**


Compound 8 was prepared from (S)-N-trifluoroacetyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine utilizing a similar procedure as described herein for the preparation of Compound 5. (S)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was obtained from (S)-N-trifluoroacetyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.17 (d, J = 8 Hz, 1H), 6.92 (d, J = 8 Hz, 1H), 3.92-3.87 (m, 1H), 3.29-3.20 (m, 2H), 3.11 (dd, J = 14, 5 Hz, 1H), 2.99 (dd, J = 14, 2 Hz, 1H), 2.74-2.65 (m, 2H), 1.32 (d, J = 7 Hz, 3H). MS calculated for C<sub>11</sub>H<sub>13</sub>BrClN+H: 274, observed: 274.

**Example 3.9: Preparation of (R)-N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 9).**



5 A solution of (R)-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.05g, 0.20 mmol) in dichloroethane (3mL) was treated with sodium triacetoxyborohydride (0.073g, 0.35 mmol) and formaldehyde (0.017 mL, 37% solution in water). This was stirred at 20°C for 2h. The reaction was diluted with 15% NaOH and extracted with ethyl acetate (2x10 mL). The organics were dried with MgSO<sub>4</sub>, filtered and concentrated to give 0.042 g as an oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.19 (d, J = 8 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 3.91-3.88 (m, 1H), 3.28 (ddd, J = 15, 12, 2 Hz, 1H), 2.99-2.88 (m, 2H), 2.68 (ddd, J = 15, 5, 1 Hz, 1H), 2.36-2.32 (m, 4H), 2.13 (t, J = 11 Hz, 1H), 1.27 (d, J = 7 Hz, 3H). MS calculated for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>N+H: 243, observed: 243.

15 **Example 3.10: Preparation of (S)-N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 10).**




**Step 1: Preparation of (S)-N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.**

20 Compound 10 was prepared from (S)-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine utilizing a similar procedure as described herein for the preparation of Compound 9. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.19 (d, J = 8 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 3.91-3.88 (m, 1H), 3.28 (ddd, J = 15, 12, 2 Hz, 1H), 2.99-2.88 (m, 2H), 2.68 (ddd, J = 15, 5, 1 Hz, 1H), 2.36-2.32 (m, 4H), 2.13 (t, J = 11 Hz, 1H), 1.27 (d, J = 7 Hz, 3H). MS calculated for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>N+H: 243, observed: 243.

25

**Example 3.11: Preparation of (S)-N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Compound 11).**





Compound **11** was prepared from (S)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine utilizing a similar procedure as described herein for the preparation of Compound **9**.  
<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18 (d, J = 8 Hz, 1H), 6.92 (d, J = 8 Hz, 1H), 3.94-3.88 (m, 1H), 3.29 (ddd, J = 15, 12, 2 Hz, 1H), 2.98-2.93 (m, 1H), 2.90 (ddd, J = 15, 6, 1 Hz, 1H), 2.36-2.32 (m, 4H) 2.13 (t, J = 11 Hz, 1H), 1.33 (d, J = 7 Hz, 3H). MS calculated for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>N+H: 288, observed: 288.

#### **Example 4 Separation of enantiomers for selected compounds of the invention**

Compounds of the present invention can be separated into their respective enantiomers using a Varian ProStar HPLC system with a 20 mm x 250 mm Chiralcel OD chiral column, eluting with 0.2 % diethylamine in various concentrations of isopropanol (IPA) in hexanes, for example, 5% IPA in hexanes, 1% IPA in hexanes and like concentrations.


It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

## CLAIMS

What we claimed is:

1. A compound of Formula (I):



wherein:

$R_1$  is H or  $C_{1-8}$  alkyl;

$R_2$  is  $C_{1-4}$  alkyl,  $-CH_2-O-C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl or  $CH_2OH$ ; and

$R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are each independently H,  $C_{1-4}$  alkyl, amino, cyano,

halogen,  $C_{1-4}$  haloalkyl, nitro or OH; or

a pharmaceutically acceptable salt, hydrate and solvate thereof;

provided that when  $R_2$  is  $C_{1-4}$  alkyl,  $-CH_2-O-C_{1-4}$  alkyl, and  $CH_2OH$  then  $R_3$

and  $R_6$  are not both hydrogen.

2. The compound according to claim 1 wherein  $R_1$  is H.
3. The compound according to claim 1 wherein  $R_1$  is  $C_{1-8}$  alkyl.
4. The compound according to claim 3 wherein  $R_1$  is methyl.
5. The compound according to claim 3 wherein  $R_1$  is ethyl.
6. The compound according to claim 3 wherein  $R_1$  is *n*-propyl.
7. The compound according to claim 3 wherein  $R_1$  is *iso*-propyl.
8. The compound according to claim 3 wherein  $R_1$  is *n*-butyl.
9. The compound according to any one of claims 1 to 8 wherein  $R_2$  is  $C_{1-4}$  alkyl.

10. The compound according to any one of claims 1 to 8 wherein  $R_2$  is methyl.
11. The compound according to any one of claims 1 to 8 wherein  $R_2$  is ethyl.
- 5 12. The compound according to any one of claims 1 to 8 wherein  $R_2$  is *iso*-propyl.
13. The compound according to any one of claims 1 to 8 wherein  $R_2$  is *n*-butyl.
14. The compound according to any one of claims 1 to 8 wherein  $R_2$  is  $C_{1-4}$  haloalkyl.
- 10 15. The compound according to any one of claims 1 to 8 wherein  $R_2$  is  $-CF_3$ .
16. The compound according to any one of claims 1 to 15 wherein  $R_3$  is H.
- 15 17. The compound according to any one of claims 1 to 15 wherein  $R_3$  is  $C_{1-4}$  alkyl.
18. The compound according to any one of claims 1 to 15 wherein  $R_3$  is  $-CH_3$ .
19. The compound according to any one of claims 1 to 15 wherein  $R_3$  is amino.
- 20 20. The compound according to any one of claims 1 to 15 wherein  $R_3$  is cyano.
21. The compound according to any one of claims 1 to 15 wherein  $R_3$  is halogen.
- 25 22. The compound according to any one of claims 1 to 15 wherein  $R_3$  is a fluorine atom.
23. The compound according to any one of claims 1 to 15 wherein  $R_3$  is a chlorine atom.
24. The compound according to any one of claims 1 to 15 wherein  $R_3$  is a bromine atom.
- 30 25. The compound according to any one of claims 1 to 15 wherein  $R_3$  is an iodine atom.
26. The compound according to any one of claims 1 to 15 wherein  $R_3$  is  $C_{1-4}$  haloalkyl.

27. The compound according to any one of claims 1 to 15 wherein  $R_3$  is  $CF_3$ .
28. The compound according to any one of claims 1 to 15 wherein  $R_3$  is nitro.
- 5 29. The compound according to any one of claims 1 to 15 wherein  $R_3$  is  $-OH$ .
30. The compound according to any one of claims 1 to 29 wherein  $R_4$  is H.
31. The compound according to any one of claims 1 to 29 wherein  $R_4$  is  $C_{1-4}$  alkyl.
- 10 32. The compound according to any one of claims 1 to 29 wherein  $R_4$  is  $-CH_3$ .
33. The compound according to any one of claims 1 to 29 wherein  $R_4$  is amino.
- 15 34. The compound according to any one of claims 1 to 29 wherein  $R_4$  is cyano.
35. The compound according to any one of claims 1 to 29 wherein  $R_4$  is halogen.
36. The compound according to any one of claims 1 to 29 wherein  $R_4$  is a fluorine atom.
- 20 37. The compound according to any one of claims 1 to 29 wherein  $R_4$  is a chlorine atom.
38. The compound according to any one of claims 1 to 29 wherein  $R_4$  is a bromine atom.
- 25 39. The compound according to any one of claims 1 to 29 wherein  $R_4$  is an iodine atom.
40. The compound according to any one of claims 1 to 29 wherein  $R_4$  is  $C_{1-4}$  haloalkyl.
41. The compound according to any one of claims 1 to 29 wherein  $R_4$  is  $CF_3$ .
- 30 42. The compound according to any one of claims 1 to 29 wherein  $R_4$  is nitro.
43. The compound according to any one of claims 1 to 29 wherein  $R_4$  is  $-OH$ .

44. The compound according to any one of claims 1 to 43 wherein  $R_5$  is H.
45. The compound according to any one of claims 1 to 43 wherein  $R_5$  is  $C_{1-4}$  alkyl.
- 5 46. The compound according to any one of claims 1 to 43 wherein  $R_5$  is  $-CH_3$ .
47. The compound according to any one of claims 1 to 43 wherein  $R_5$  is amino.
48. The compound according to any one of claims 1 to 43 wherein  $R_5$  is cyano.
- 10 49. The compound according to any one of claims 1 to 43 wherein  $R_5$  is halogen.
50. The compound according to any one of claims 1 to 43 wherein  $R_5$  is a fluorine atom.
- 15 51. The compound according to any one of claims 1 to 43 wherein  $R_5$  is a chlorine atom.
52. The compound according to any one of claims 1 to 43 wherein  $R_5$  is a bromine atom.
53. The compound according to any one of claims 1 to 43 wherein  $R_5$  is an iodine atom.
- 20 54. The compound according to any one of claims 1 to 43 wherein  $R_5$  is  $C_{1-4}$  haloalkyl.
55. The compound according to any one of claims 1 to 43 wherein  $R_5$  is  $CF_3$ .
- 25 56. The compound according to any one of claims 1 to 43 wherein  $R_5$  is nitro.
57. The compound according to any one of claims 1 to 43 wherein  $R_5$  is  $-OH$ .
58. The compound according to any one of claims 1 to 57 wherein  $R_6$  is H.
- 30 59. The compound according to any one of claims 1 to 57 wherein  $R_6$  is  $C_{1-4}$  alkyl.
60. The compound according to any one of claims 1 to 57 wherein  $R_6$  is  $-CH_3$ .

61. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is amino.
62. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is cyano.
- 5 63. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is halogen.
64. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is a fluorine atom.
65. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is a chlorine atom.
- 10 66. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is a bromine atom.
67. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is an iodine atom.
- 15 68. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is C<sub>1-4</sub> haloalkyl.
69. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is CF<sub>3</sub>.
70. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is nitro.
- 20 71. The compound according to any one of claims 1 to 57 wherein R<sub>6</sub> is -OH.
72. The compound of claim 1 selected from the group consisting of:  
6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
25 6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and  
8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.
73. The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-  
30 benzazepine.
74. The compound of claim 1 selected from the group consisting of:  
N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and  
N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

75. The compound according to any one of claims 1 to 74 wherein said compound is an *R* enantiomer.
- 5 76. The compound according to any one of claims 1 to 74 wherein said compound is an *S* enantiomer.
77. A pharmaceutical composition comprising a compound according to any one of claims 1 to 76 and a pharmaceutically acceptable carrier.
- 10 78. A method of modulating a 5HT<sub>2C</sub> receptor comprising contacting said receptor with a therapeutically effective amount of a compound according to any one of claims 1 to 76.
79. The method according to claim 78 wherein said compound is an agonist of said receptor.
- 15 80. A method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount of a compound according to any one of claims 1 to 76 or a pharmaceutical composition according to claim 77.
- 20 81. The method according to claim 80 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.
- 25 30 82. The method according to claim 81 wherein the disorder of the central nervous system is obesity.

83. The method according to claim 81 wherein the disorder of the central nervous system is Alzheimer disease.
84. The method according to claim 81 wherein the sexual dysfunction is Male erectile  
5 dysfunction.
85. The method according to claim 80 wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases, toxic CNS diseases or infective CNS diseases.
- 10 86. The method according to claim 80 wherein the damage to the central nervous system is by encephalitis or meningitis.
87. The method according to claim 80 wherein the cardiovascular disorder is thrombosis.
- 15 88. The method according to claim 80 wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.
89. The method according to one of claims 80 to 88 wherein said individual is a mammal.
- 20 90. The method according to claim 89 wherein said mammal is a human.
91. A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to any one of claims 1 to 76 or a pharmaceutical composition according to claim 77.
- 25 92. The method according to one of claims 91 wherein said individual is a mammal.
93. The method according to claim 92 wherein said mammal is a human.
- 30 94. A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to any one of claims 1 to 76 or a pharmaceutical composition according to claim 77.
95. The method according to one of claims 94 wherein said individual is a mammal.



96. The method according to claim 95 wherein said mammal is a human.
- 5 97. A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to any one of claims 1 to 76 or a pharmaceutical composition according to claim 77.
- 10 98. The method according to one of claims 97 wherein said individual is a mammal.
99. The method according to claim 98 wherein said mammal is a human.
100. The method according to any one of claims 93, 96 and 99 wherein the human has a body mass index of about 18.5 to about 45.
- 15 101. The method according to any one of claims 93, 96 and 99 wherein the human has a body mass index of about 25 to about 45.
102. The method according to any one of claims 93, 96 and 99 wherein the human has a body mass index of about 30 to about 45.
- 20 103. The method according to any one of claims 93, 96 and 99 wherein the human has a body mass index of about 35 to about 45.
- 25 104. A method of producing a pharmaceutical composition comprising admixing at least one compound according to any one of claims 1 to 76 and a pharmaceutically acceptable carrier.
105. A compound according to any one of claims 1 to 76 for use in a method of treatment of the human or animal body by therapy.
- 30 106. A compound according to any one of claims 1 to 76 for use in a method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea of the human or animal body by therapy.

107. The use according to claim 106 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.
108. The use according to claim 107 wherein the disorder of the central nervous system is obesity.
109. The method according to claim 107 wherein the disorder of the central nervous system is Alzheimer disease.
110. The method according to claim 107 wherein the sexual dysfunction is Male erectile dysfunction.
111. The use according to claim 106 wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases, toxic CNS diseases or infective CNS diseases.
112. The use according to claim 106 wherein the damage to the central nervous system is by encephalitis or meningitis.
113. The use according to claim 106 wherein the cardiovascular disorder is thrombosis.
114. The use according to claim 106 wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.
115. A use of a compound according to any one of claims 1 to 76 for the manufacture of a medicament for use in the treatment or prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal

disorders; diabetes insipidus or sleep apnea.

116. The use according to claim 115 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.
117. The use according to claim 116 wherein the disorder of the central nervous system is obesity.
118. The method according to claim 116 wherein the disorder of the central nervous system is Alzheimer disease.
119. The method according to claim 116 wherein the sexual dysfunction is Male erectile dysfunction.
120. The use according to claim 115 wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases, toxic CNS diseases or infective CNS diseases.
121. The use according to claim 115 wherein the damage to the central nervous system is by encephalitis or meningitis.
122. The use according to claim 115 wherein the cardiovascular disorder is thrombosis.
123. The use according to claim 115 wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/019670

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D223/16 A61K31/55 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| P, X       | KRULL, OLAF ET AL: "Synthesis and structure/NMDA receptor affinity relationships of 1-substituted tetrahydro-3-benzazepines"<br>BIOORGANIC & MEDICINAL CHEMISTRY, 12(6), 1439-1451 CODEN: BMECEP; ISSN: 0968-0896, 2004, XP002306863<br>abstract<br>page 1442; table 2 | 1-123                 |
| P, X       | WO 03/086306 A2 (ARENA PHARMACEUTICALS, INC., USA) 23 October 2003 (2003-10-23)<br>abstract<br>examples<br>claims  | 1-123                 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

22 November 2004

Date of mailing of the international search report

09/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stix-Malaun, E

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/019670

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | CHANG, WEI K. ET AL: "Dopamine receptor binding properties of some 2,3,4,5-tetrahydro-1H-3- benzazepin-7-ols with nonaromatic substituents in the 5-position"<br>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS ,<br>2(5), 399-402 CODEN: BMCLE8; ISSN:<br>0960-894X, 1992, XP002306864<br>abstract<br>page 401; table 1<br>----- | 1-123                 |
| X          | EP 0 285 919 A1 (SCHERING CORP., USA)<br>12 October 1988 (1988-10-12)<br>abstract<br>examples; tables<br>claims<br>-----  | 1-123                 |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/019670

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 78-104, 107-114 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/019670

| Patent document<br>cited in search report |    | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|----|---------------------|--|--|
| WO 03086306                               | A2 | 23-10-2003          | US 2003225057 A1<br>EP 1411881 A2  | 04-12-2003<br>28-04-2004   |
| EP 0285919                                | A1 | 12-10-1988          | AT 112766 T<br>AU 619744 B2<br>AU 1596488 A<br>CA 1321195 C<br>DE 3851769 D1<br>DK 652688 A ,B,<br>EP 0357641 A1<br>FI 894566 A<br>HU 53882 A2<br>IL 85855 A<br>JP 2502723 T<br>JP 6062574 B<br>KR 9311489 B1<br>MX 9203394 A1<br>NO 885096 A ,B,<br>NZ 224038 A<br>PH 27337 A<br>PT 87068 A ,B<br>WO 8807526 A1<br>US 5015639 A<br>US 5247080 A<br>ZA 8802080 A | 15-10-1994<br>06-02-1992<br>02-11-1988<br>10-08-1993<br>17-11-1994<br>23-11-1988<br>14-03-1990<br>27-09-1989<br>28-12-1990<br>21-02-1993<br>30-08-1990<br>17-08-1994<br>08-12-1993<br>01-07-1992<br>15-11-1988<br>26-10-1990<br>08-06-1993<br>01-04-1988<br>06-10-1988<br>14-05-1991<br>21-09-1993<br>26-04-1989 |